The QualityStocks Daily Monday, June 10th, 2024

Today's Top 3 Investment Newsletters

Premium Stock Alerts(DSY) $3.6100 +89.09%

Tip.us(HLYK) $0.0870 +65.71%

MarketClub Analysis(PRSTW) $0.0383 +47.31%

The QualityStocks Daily Stock List

Research Frontiers (REFR)

SmarTrend Newsletters, QualityStocks, StockMarketWatch, SmallCapVoice, TraderPower, TradersPro, MarketClub Analysis, TradersPro Morning, Investing Futures, Investor Update, MarketBeat, Marketbeat.com, Greenbackers, Zacks, StreetAuthority Daily, StreetInsider, TopStockAnalysts and PennyOmega reported earlier on Research Frontiers (REFR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Research Frontiers, Inc. (NASDAQ: REFR) is focused on the development and marketing of devices and technology that control the flow of light.

The firm has its headquarters in Woodbury, New York and was incorporated in October 1965 by Robert L. Saxe. It serves consumers across the globe.

The company has almost 40 firms that are licensed to mainly serve 5 application areas for its products, namely the display, marine, automotive, architectural and aerospace sectors. It has about 245 patents which have been issued globally as well as patent applications in the U.S. and other countries. Most of the company’s revenue is generated from licensing its technology. For instance, the company granted Diamond Glass a license to manufacture and sell SPD-SmartGlass smart window products in Europe.

The enterprise develops SPD-Smart light-control technology (suspended particle device) which can be used in different product applications, such as flat panel displays for electronics; eyewear products and museum display panels, aircraft windows, navigation systems, instrument panels, rear-view mirrors, sunshades, sun-visors, sunroofs and automotive windows, interior partitions for buildings and homes, skylights, sunshades and windows. It licenses this technology to firms which are involved in manufacturing and marketing SPD-Smart chemical emulsion. This emulsion is used to make a light-control film, which is then laminated to make light-control panels.

The company recently announced its second quarter financial results which show decreases in net loss and total expenses. As the inventor of patented SPD SmartGlass technology, the company is set to generate revenue from its products both in the short and long term, which will be good for its growth and investments.

Research Frontiers (REFR), closed Monday's trading session at $2, up 17.6471%, on 83,078 volume. The average volume for the last 3 months is 79,066 and the stock's 52-week low/high is $0.90/$2.4147.

NervGen Pharma Corp. (NGENF)

QualityStocks, TradersPro, MarketBeat and AllPennyStocks reported earlier on NervGen Pharma Corp. (NGENF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

NervGen Pharma Corp. is a regenerative medicine company listed on the OTC Markets Group’s OTCQX. The Company’s commitment is to creating leading-edge solutions for the treatment of nerve damage. This includes spinal cord and peripheral nerve injury. The Company’s lead compound is NVG-291. NervGen Pharma has its corporate headquarters in Vancouver, British Columbia.

NervGen’s core technology targets protein tyrosine phosphatase sigma (PTPσ). This is a neural receptor that impedes nerve regeneration. Inhibition of the PTPσ receptor has been shown to promote regeneration of damaged nerves and improvement of nerve function in animal models for diverse medical conditions. Research has been conducted on other applications of PTPs including MS, stroke, cardiac arrhythmia, and Alzheimer’s Disease.

In addition, the Company continues to research secondary applications including multiple sclerosis, acute myocardial infarction induced arrhythmia (AMI, normally known as a heart attack), stroke and other neurodegenerative diseases. NervGen’s plan is to begin a Phase 1 human clinical trial for its lead compound, NVG-291, in early 2020 under an Investigational New Drug application with the US Food and Drug Administration (FDA).

NervGen Pharma Corp. (NGENF), closed Monday's trading session at $1.7, up 16.4384%, on 235,479 volume. The average volume for the last 3 months is 13,455 and the stock's 52-week low/high is $1.16/$2.99.

XWELL Inc. (XWEL)

The Online Investor and QualityStocks reported earlier on XWELL Inc. (XWEL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

XWELL Inc. (NASDAQ: XWEL) (FRA: V9G) is a health and wellness services firm that is engaged in the provision of spa services at airports globally.

The firm has its headquarters in New York and was incorporated in 2006, on January 9th by David Goldfarb and Jonathan Medved. Prior to its name change in October 2022, the firm was known as XpresSpa Group Inc. It operates as part of the personal services industry, under the consumer cyclical sector. The firm serves consumers in the United States, the United Arab Emirates and Holland.

The company operates through the XpresSpa, Treat, XpresTest and HyperPointe segments. The XpresSpa segment offers travelers premium spa services, including massage, nail and skin care, as well as spa and travel products while the Treat segment comprises of access to integrated care designed to deliver on-demand access to integrated healthcare through technology and personalized services. On the other hand, the XpresTest segment deals with diagnostic COVID-19 tests at XpresCheck Wellness Centers in airports, to airport employees and to the traveling public. HyperPointe is a digital healthcare and data analytics relationship firm serving the global healthcare industry.

The enterprise’s spa services include massage, and nail and skin care, as well as spa and travel products; and retail products. As of December 2021, it operated 52 spa and clinic locations in 24 airports in the Netherlands, the United States and the United Arab Emirates.

The company has partnered with Human Touch and HydroMassage manufacturers to introduce fully customizable and autonomous services in select locations in the U.S. This move will not only extend the company’s reach but also open it up to new growth and investment opportunities.

XWELL Inc. (XWEL), closed Monday's trading session at $1.79, up 14.7436%, on 64,133 volume. The average volume for the last 3 months is 173,215 and the stock's 52-week low/high is $1.26/$6.40.

Semler Scientific, Inc. (SMLR)

QualityStocks, Wall Street Resources, MarketBeat, Top Pros' Top Picks, StreetInsider, StockEarnings, Money Wealth Matters, Money Morning, MarketClub Analysis, Marketbeat.com, InsiderTrades, Daily Trade Alert and Barchart reported earlier on Semler Scientific, Inc. (SMLR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Semler Scientific, Inc. is a medical risk-assessment Company headquartered in San Jose, California. Its mission is to develop, manufacture, and market patented products that identify the risk profile of medical patients to allow healthcare providers to capture full reimbursement potential for their services. Semler Scientific provides technology and software solutions to improve the clinical effectiveness of healthcare insurers and physician groups. Semler Scientific lists on the OTC Markets Group’s OTCQB.

In essence, Semler Scientific provides diagnostic and testing services to the U.S.’s leading health plans and providers. The Company’s goal is to develop, manufacture, and market innovative proprietary products and services, which assist its customers in evaluating and treating chronic diseases.

Semler Scientific manufactures the QuantaFlo system for Vascular Disease testing. The QuantaFlo system is very suitable for use in primary care offices, specialty practices, health fairs, or during home assessments. 

The QuantaFlo PAD test delivers quick, accurate results in approximately five minutes at the point of care. In March 2015,  The Company received Food and Drug Administration (FDA)  510 (k) clearance for the next generation version of QuantaFlo, which commercially launched in August 2015. The QuantaFlo software can be installed on any Windows based PC, laptop or tablet.

Semler Scientific's first patented and FDA cleared product, introduced commercially in 2011, measured arterial blood flow in the extremities to aid in the diagnosis of peripheral arterial disease.

Semler Scientific, Inc. (SMLR), closed Monday's trading session at $36.28, up 14.7012%, on 1,518,540 volume. The average volume for the last 3 months is 542,877 and the stock's 52-week low/high is $20.88/$53.38.

Lixte Biotechnology (LIXT)

QualityStocks, TopPennyStockMovers, MarketClub Analysis, PennyStockScholar, StocksEarning, Fierce Analyst, HotOTC, INO Market Report, Money Wealth Matters, OTCtipReporter, Penny Pick Finders, PennyStockProphet, Buzz Stocks, PoliticsAndMyPortfolio.com, Wall Street Mover, Profitable Trader Authority, Real Pennies, Small Cap Firm, StockOnion, StockWireNews and PoliticsAndMyPortfolio reported earlier on Lixte Biotechnology (LIXT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Lixte Biotechnology Holdings Inc. (NASDAQ: LIXT) (FRA: 864) is a drug discovery firm that utilizes biomarker technology to identify enzyme targets associated with severe common ailments and design new compounds to attack these targets.

The firm has its headquarters in East Setauket, New York and was incorporated in 2005, on August 5th by Robert B. Royds and John S. Kovach. It operates as part of the pharmaceutical and medicine manufacturing industry, under the healthcare sector. The firm has three companies in its corporate family and serves consumers in the United States.

The company is party to a collaboration agreement with Oncode Institute, the Netherlands Cancer Institute, and the Spanish Sarcoma Group. It is also party to a clinical trial research agreement with the Research Institute Hospital Inc. and the Moffitt Cancer Center.

The enterprise mainly focuses on protein phosphatases inhibitors which can be used solely or in combination with immune checkpoint blockers, x-ray and/or cytotoxic agents. Its products portfolio is comprised of 2 major categories of compounds that are in different stages of clinical and pre-clinical development. The enterprise develops 2 series of pharmacologically active drugs, which include the LB-200 series for the treatment of cancer, neurodegenerative ailments and chronic hereditary illnesses like Gaucher’s disease; and the LB-100 series, which is made up of new structures that may be useful in the treatment of cancers, as well as metabolic and vascular illnesses.

The company recently announced its latest results from its LB-100 preclinical study which show that the compound grew responsiveness of diverse cancers to immunotherapy. As most patients with cancer don’t respond to immunotherapy, this advancement is a breakthrough in the development of a more effective cancer treatment, which will benefit patients with cancer while boosting the company’s growth.

Lixte Biotechnology (LIXT), closed Monday's trading session at $2.42, up 14.6919%, on 47,366 volume. The average volume for the last 3 months is 233,750 and the stock's 52-week low/high is $1.58/$9.50.

Dogness International (DOGZ)

TradersPro, MarketClub Analysis, QualityStocks, StreetInsider, TopPennyStockMovers, StockMarketWatch, Schaeffer's, InvestorPlace and FreeRealTime reported earlier on Dogness International (DOGZ), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Dogness International Corp. (NASDAQ: DOGZ) is focused on designing, manufacturing and selling smart and fashionable products for pets.

The firm has its headquarters in Dongguan, the People’s Republic of China and was incorporated in 2003 by Shilong Chen. The firm serves consumers around the globe.

The company’s objective is to build the future of pet commerce by innovating its traditional product line while leveraging its proven research and development capabilities to gain leadership in pet Internet of Things. It produces high-quality harnesses, collars and leashes that are comfortable, beautiful and designed to ensure pet owners’ peace of mind and pet safety. The company operates through its subsidiaries.

The enterprise produces products in Special function, Holiday, LED, Luxury, Elegance, Cat and Classic series. They include pet harnesses, pet collars, retractable leashes, lanyards and pet leashes; pet belt ribbons, elastic belts, laces, high-grade textiles and computer jacquard ribbons; gift suspenders; pet charms and mouth covers; climbing hooks; pet shampoos; and intelligent pet products like pet water fountains, app-controlled pet feeders and smart pet toys. It also provides the anti-shock leash, the H2 smart harness and the C2 smart collar. The enterprise has designed its smart collars to allow owners to find their dogs easily. It provides its products to retailers and wholesalers.

The company recently announced that it would be expanding the availability of its smart pet products online and in stores, building on its existing supplier relationships. This move will help extend the company’s consumer reach, which will not only bring in more revenue into the company but also drive its growth.

Dogness International (DOGZ), closed Monday's trading session at $16.04, up 13.7589%, on 569,575 volume. The average volume for the last 3 months is 22,396 and the stock's 52-week low/high is $2.785/$17.60.

Akari Therapeutics (AKTX)

StockMarketWatch, MarketBeat, TraderPower, MarketClub Analysis, StockEarnings, StocksEarning, Barchart, BUYINS.NET, Schaeffer's, QualityStocks, AllPennyStocks, PoliticsAndMyPortfolio, Buzz Stocks, Daily Trade Alert, HotOTC, OTCtipReporter, Penny Pick Finders, PennyStockScholar, Profitable Trader Authority, Schaeffer’s, Small Cap Firm, StockOnion and PennyStockProphet reported earlier on Akari Therapeutics (AKTX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Akari Therapeutics PLC (NASDAQ: AKTX) (FRA: US972G108) is a clinical stage biopharmaceutical firm that is focused on developing and commercializing treatments for rare and orphan inflammatory and autoimmune illnesses, including atypical Hemolytic Uremic Syndrome, Guillain Barre syndrome and paroxysmal nocturnal hemoglobinuria, which are brought about by dysregulation of C5 (complement component 5).

The company has its headquarters in London, the United Kingdom and was incorporated in 2004, on October 7th. It markets its products in the U.K. and the United States and generates most of its revenue from the U.K.

The firm’s products include a second-generation complement inhibitor which prevents both terminal complement activation and leukotriene B4, dubbed Nomacopan. It does so by tightly bonding to C5 and hindering its activation and cleavage by complement. Its other products include Coversin dual action, Coversin long acting and Coversin. The latter is currently in its phase 2 clinical trial evaluating its efficacy in treating inflammatory and autoimmune ailments.

The company recently announced that the FDA (Food and Drug Administration) had awarded their Nomacopan candidate a fast-track designation for its use in treating patients with severe or moderate BP. This comes after the candidate was also awarded the same designation by the European Medicines Agency. BP is a serious autoimmune inflammatory blistering skin disease that has no approved treatments in Europe and the U.S. The candidate’s success may possibly open up a range of other serious dermatological conditions that can be treated using Nomacopan, while also addressing a previously unmet need, which will make it very popular among patients who suffer from this ailment.

Akari Therapeutics (AKTX), closed Monday's trading session at $2.52, up 12.9994%, on 70,958 volume. The average volume for the last 3 months is 67,193 and the stock's 52-week low/high is $1.0775/$5.50.

enGene Holdings (ENGN)

MarketBeat and InvestorPlace reported earlier on enGene Holdings (ENGN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

enGene Holdings Inc. (NASDAQ: ENGN) (NASDAQ: ENGNW) is a clinical-stage biotechnology firm focused on the development of genetic medicines through the delivery of therapeutics to mucosal tissues and other organs.

The firm has its headquarters in Saint-Laurent, Canada and was incorporated in 2023, on April 24th by Anthony T. Cheung. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers primarily in Canada and the United States.

The company focuses on overcoming the limitations of viral-based gene therapies and advancing gene therapy beyond rare genetic illnesses into the mainstream of clinical practice. Its proprietary dually-derived chitosan (DDX) platform has a high degree of payload flexibility, including DNA and various forms of RNA with broad tissue and disease application. In preclinical animal and in vitro models, its DDX technology has been demonstrated to effectively induce expression of therapeutic genes following delivery to the lung, gastrointestinal tract, and urinary tract.

The enterprise’s lead product detalimogene voraplasmid (EG-70) is being developed for the treatment of bacillus calmette-guerin (BCG)-resistant non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). EG-70 is a novel non-viral gene therapy designed to elicit a local immune response following the delivery to the bladder urothelium.

The firm recently released its latest financial results, with its CEO revealing that they had raised $200 million from top tier investors in a private financing, and they remained committed to pursuing pipeline expansion through additional EG-70 development opportunities and possible new research and development programs. This may attract additional investments into the firm while also generating additional value for its shareholders.

enGene Holdings (ENGN), closed Monday's trading session at $7.91, off by 6.9412%, on 50,499 volume. The average volume for the last 3 months is 557,988 and the stock's 52-week low/high is $6.69/$43.00.

Trulieve Cannabis Corp. (TCNNF)

QualityStocks, InvestorPlace, MarketBeat, Wealth Insider Alert, Daily Trade Alert, Top Pros' Top Picks, Cabot Wealth, The Street, Trades Of The Day, Profit Trends, TradersPro, The Online Investor, StreetInsider, Prism MarketView and CannabisNewsWire reported earlier on Trulieve Cannabis Corp. (TCNNF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A new study exploring the potential of marijuana terpenes as treatments for chronic neuropathic pain suggests that these compounds could be as effective as morphine for pain relief, showing similar reductions in pain markers when administered via injection. Interestingly, when terpenes were combined with morphine, they enhanced the drug’s effectiveness as well.

The study found that, unlike morphine, none of the terpenes triggered a significant reward response, implying that they might be effective pain relievers without the risk of addiction or dysphoria. However, vaporized or orally administered terpenes did not show much impact on pain relief.

The authors highlighted that while major marijuana components, such as CBD and THC, have shown moderate effectiveness in managing severe pain, THC often has undesirable psychoactive effects. This limitation has led to a focus on other potential therapeutic compounds in marijuana, including terpenes, flavonoids and minor cannabinoids.

Terpenes, naturally occurring in many plants, such as rosemary, pine trees and oranges, are particularly abundant in marijuana, which contains about 150 different terpenes. The study suggests that this chemical diversity might contribute to the varied effects of various marijuana strains.

The research specifically investigated five terpenes: linalool, alpha-humulene, geraniol, beta-caryophyllene and beta-pinene, found in significant quantities in marijuana. The terpenes were tested on mice to evaluate their effects on inflammatory and peripheral neuropathic pain. The substances were injected into the mice’s hind paws and induced by chemotherapy medications, respectively. The terpenes were also administered orally and through vaporization.

Tests were conducted on a per-terpene basis, with 200 mg/kg of terpenes and 10 mg/kg of morphine being used for comparison. The study aimed to not only assess pain relief but also understand the mechanisms behind it. This included behavioral observations and cellular analyses, such as mRNA evaluation from flash-frozen mouse skin.

Results showed that all tested terpenes reduced neuropathic pain markers, except pinene, which did not significantly affect inflammatory pain.

Combining lower doses of terpenes with morphine appeared to enhance pain relief, indicating a potential for combination therapies that might offer better pain management while reducing the risk of opioid addiction. Regarding the potential for addiction, the study found that linalool and geraniol did not produce either an aversion or a preference in mice, suggesting they do not cause dysphoria or reward. Conversely, beta-caryophyllene and alpha-humulene showed a substantial aversive response, indicating they might be dysphoric, while beta-pinene had possible aversive side effects.

The method of administering terpenes mattered significantly. Injected terpenes were effective in reducing pain markers, whereas oral and vaporized terpenes had limited impact and sometimes caused side effects such as hypothermia. This indicates that terpenes might have restricted bioavailability when taken orally or inhaled, which could explain why some people might not experience their pain-relieving effects through these methods.

The study also explored the mechanisms behind terpene-induced pain relief, suggesting that terpenes might act as anti-inflammatory agents and interact with specific nervous system receptors. The research indicated that terpenes could act as A2AR agonists, potentially interacting with receptors in a complex manner that requires further investigation.

Overall, while the findings are promising, the authors emphasized the need for more research to fully understand how these results translate to human pain management.

This study, in a way, provides validation for companies such as Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) that have heavily invested in developing medical cannabis products to help patients manage their symptoms.

Trulieve Cannabis Corp. (TCNNF), closed Monday's trading session at $9.57, up 4.5902%, on 522,437 volume. The average volume for the last 3 months is 24.516M and the stock's 52-week low/high is $3.42/$14.50.

Lucid Motors (LCID)

Green Car Stocks, InvestorPlace, StockEarnings, Schaeffer's, QualityStocks, The Street, MarketBeat, Early Bird, MarketClub Analysis, StocksEarning, GreenCarStocks, Investopedia, INO Market Report, Daily Trade Alert, Kiplinger Today, The Online Investor, Money Wealth Matters, Trades Of The Day, BillionDollarClub, The Wealth Report, Louis Navellier, Zacks, The Night Owl, DividendStocks, FreeRealTime, Cabot Wealth, Wealth Whisperer, Top Pros’ Top Picks, The Stock Dork, InsiderTrades, InvestorsUnderground, AllPennyStocks, Smartmoneytrading and Green Energy Stocks reported earlier on Lucid Motors (LCID), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

While new electric vehicle sales have been declining for several months amid high interest rates and purchase prices, green-energy proponents could draw some comfort from the fact that consumers are turning to the used-EV market in droves. Thanks to a confluence of factors, including falling prices in the secondhand electric-vehicle market along with tax breaks, used EVs are seeing a resurgence in sales.

Buying a used vehicle is the only way most American drivers will be able to own an EV. With the average new electric car costing at least $10,000 more than a similar fossil-fuel vehicle, the majority of drivers in the U.S. simply cannot afford to go electric. Even with government subsidies and tax breaks, the costs involved in buying a new battery electric vehicle (BEV) tend to be so high that most of the U.S. market is locked out of owning a new BEV.

Used electric cars present a great opportunity for ecofriendly drivers to switch to EVs without having to break the bank. As such, the key to a robust used-EV market is affordability. Now that used electric vehicle prices are declining around the country and in other major markets, chiefly due to price cuts initiated by American automaker Tesla, customers are buying up more secondhand electric cars.

After Tesla entered a price discount war with Chinese automakers such as BYD and cut prices across several markets, new EV prices as a whole began to decline. Since secondhand market values are often affected by new EV prices, the discount war also caused prices for used electric cars to drop. Taking advantage of local and federal incentives has made used EVs even more accessible to drivers with limited budgets.

The $4,000 tax credit for new EV purchases is now available for used EVs as well, and it came at the right time. Thanks to legislative changes made last year, customers can now access this tax break at the point of sale instead of buying at full price and waiting months for the tax breaks to kick in. This made accessing the crucial tax break a lot easier and opened up EV ownership to drivers who couldn’t afford to wait until tax season.

According to auto website Cars.com, customer searchers for used electric cars on its dealer listings have increased by 45% since 2023. TrueCar has also noted a 39% increase in electric-vehicle searchers in Q1 2024 compared to Q1 2023, while used-vehicle site Carvana reports a 100% increase in used-electric-vehicle sales since 2023. Drivers are purchasing more used electric cars while the new EV market struggles to attract customers.

The uptick in used EV sales could be a positive signal to electric-vehicle makers such as Lucid Motors (NASDAQ: LCID) regarding the future prospects of BEVs since the future could be uncertain if the used models weren’t attracting more buyers as well.

Lucid Motors (LCID), closed Monday's trading session at $2.73, even for the day, on 13,516,956 volume. The average volume for the last 3 months is 871,128 and the stock's 52-week low/high is $2.29/$8.37.

Curaleaf Holdings Inc. (CURLF)

InvestorPlace, QualityStocks, Kiplinger Today, MarketBeat, Cabot Wealth, Daily Trade Alert, Top Pros' Top Picks, The Online Investor, MarketClub Analysis, Profit Trends, Wealth Insider Alert, StreetInsider, Early Bird, Trading For Keeps, Trades Of The Day, The Street, Prism MarketView, TradersPro, Zacks, Schaeffer's, Investment U, StreetAuthority Daily, wyatt research newsletter, Daily Profit, CFN Media Group, CannabisNewsWire and Wyatt Investment Research reported earlier on Curaleaf Holdings Inc. (CURLF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

New research has determined that recreational cannabis legalization in some states has led to an increase in enrolments by roughly 9%, without compromising rates of graduation or degree completion. The research was carried out by Ahmed El Fatmaoui, a graduate student at the University of Oklahoma.

For the study, El Fatmaoui built on previous research such as one study that determined which legal states saw bigger application pools with no observed decline in student-applicant quality. He then obtained data from the Integrated Postsecondary Education Data system as well as the county for his analysis.

His findings showed that the legalization of recreational cannabis increased enrolment by between 4% to 9%, with the researcher noting that this was observed in both women and men. The report explained that enrolments rose after the fourth year of the first dispensary in a state launching, highlighting that the delay could be because of various factors, including the moderate development of a cannabis consumption culture.

El Fatmaoui also recognized that another possible explanation could be the fact that states sometimes used supplementary tax revenue generated from cannabis sales to subsidize their higher-education sector. This, he posited, could also increase enrollment numbers.

Regarding student performance, the research centered on Colorado and Washington, primarily because they are the only states that have legalized recreational cannabis for a long enough period. El Fatmaoui determined that the legalization of recreational cannabis had a positive impact on rates of graduation, contributing to increases of more than 5% and 2.7% points for associate degrees and bachelor’s degrees respectively.

The researcher explained that the increase in the graduation rate for bachelor’s degrees reflected growing student transfers, adding that rising out-of-state enrollments also suggested that the shift in policy boosted competitiveness in colleges by providing positive amenities.

He underscored that there was no evidence that the legalization of recreational cannabis affected in-state enrollment, quality or college prices. He then added that his findings didn’t negate results of past studies, explaining that lack of data on grade point average data in the dataset he used prevented him from evaluating the impact of recreational cannabis legalization on overall student scores.

In his conclusion, El Fatmaoui wrote that his analysis revealed that the legalization of recreational cannabis did not diminish overall student success.

He also called attention to the need for additional studies on how this change in policy impacted student choice when it came to choosing majors. The study’s findings were reported in the “Economic Inquiry” journal.

This study sheds additional light on the unexpected benefits that can accrue when a robust cannabis market is launched and licensed companies such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) are allowed to operate.

Curaleaf Holdings Inc. (CURLF), closed Monday's trading session at $4.42, off by 1.559%, on 261,592 volume. The average volume for the last 3 months is 432,750 and the stock's 52-week low/high is $2.51/$6.40.

Royal Gold Inc. (RGLD)

TopStockAnalysts, Streetwise Reports, StreetAuthority Daily, InvestorPlace, QualityStocks, TradingAuthority Daily, Top Pros' Top Picks, MarketBeat, The Street, Daily Wealth, StreetInsider, Daily Trade Alert, SmarTrend Newsletters, Zacks, All about trends, TheStockAdvisor, Energy and Capital, Money Morning, MarketClub Analysis, The Growth Stock Wire, TheStockAdvisors, DividendStocks, Trades Of The Day, Dividend Opportunities, Wyatt Investment Research, Marketbeat.com, Uncommon Wisdom, MiningNewsWire, Barchart, Wealth Daily, Stansberry Research, Lebed.biz, Investor Update, Schaeffer's, Daily Profit, Investment U, National Inflation Association, Stockhouse, The Online Investor, Traders For Cash Flow, Money and Markets, TradingMarkets, Trade of the Week, Market Intelligence Center Alert, Forbes, Greenbackers, Outsider Club, Weekly Wizards, Kiplinger Today, FNNO Newsletters, Eagle Financial Publications, Dynamic Wealth Report, TradersPro, Bourbon and Bayonets, BestChartNow, Wealth Insider Alert, ChartAdvisor, AllPennyStocks, Investopedia, Penny Stock Chaser, PowerRatings Stocks, Profits Run, Short Term Wealth, Market FN, Market Authority, GorillaTrades, StocksEarning, FreeRealTime, The Best Newsletters, Investing Futures, Inside Investing Daily, INO.com Market Report, One Hot Stock, Hit and Run Candle Sticks and Stocks That Move reported earlier on Royal Gold Inc. (RGLD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Earlier this month, the price of gold rose as weaker than expected data on the U.S. economy strengthened expectations that the Fed would reduce rates of interest later this year, which sent bond yields and the dollar even lower.

The price of spot gold rose by 0.9% to reach $2,347.10 an ounce. This is after it posted a 2% increase in May, with prices reaching a new high of $2,449.89 towards the end of May. U.S. gold futures also rose by 1% to reach $2,369.30 an ounce.

Latest data shows that manufacturing activity in America slowed for a second month in May, with this being attributed to a decline in new orders. May’s manufacturing purchasing managers index under the Institute for Supply Management dropped to 48.7 from April’s figure. Construction spending also fell unexpectedly in April after a drop in nonresidential activity was recorded. This despite seeing an improvement in single-family home building.

Data from the Commerce Department’s Census Bureau showed that construction spending fell 0.1% after slipping 0.2% in March. Benchmark U.S. Treasury yields declined to a two-week low after weak manufacturing data was posted, while the dollar also dropped to a three-week low against other currencies. This made gold even more attractive for holders of other currencies.

Data from Friday showed that in April, inflation in America stabilized, suggesting that the central bank’s plans to cut interest rates later this year was still set. High Ridge Futures’ director of alternative investments and trading, David Meger, stated that despite some pullback, there were strong expectations that the country is inching closer to reduced interest rates later this year.

Traders speculate that there’s about a 59% likelihood of a rate cut by the Federal Reserve in September. Lower rates of interest reduce the opportunity cost of holding nonyielding bullion.

In other news, the European Central Bank is expected to reduce interest rates to 3.75%. This is based on a poll of economists who forecasted two reductions set for September and December. This move shall make it the first major central bank to reduce rates this cycle.

Investors now wait for U.S. nonfarm payrolls due later this week as well as the ADP employment report.

Palladium also rose by 1.6% to reach $918.6 per ounce while the price of spot silver rose by 0.7% to hit $30.5 an ounce. The price of platinum dropped by 1.9% to reach $1,017.5 per ounce.

As central banks around the world move to cut rates, gold will become more attractive as an investment. As a result, entities such as Royal Gold Inc. (NASDAQ: RGLD) could deliver commendable shareholder value as bullish conditions continue.

Royal Gold Inc. (RGLD), closed Monday's trading session at $123.64, off by 0.0485044%, on 394,823 volume. The average volume for the last 3 months is 553,465 and the stock's 52-week low/high is $100.55/$134.56.

The QualityStocks Company Corner

Annovis Bio Inc. (NYSE: ANVS)

The QualityStocks Daily Newsletter would like to spotlight Nightfood Holdings Inc. (NYSE: ANVS).

Annovis Bio (NYSE: ANVS), a late-stage, clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's disease ("AD") and Parkinson's disease ("PD") will host an investor webcast. According to the announcement, during the webcast, Annovis Bio officials will discuss recent advancements in the development of Buntanetap, the company's lead drug candidate, as well as strategic plans for upcoming clinical trials and an overview of the company's progress along with its future direction. The call is slated for June 11, 2024, at 4:30 p.m. ET. Buntanetap has been formulated to target neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein and TDP43. By improving synaptic transmission and axonal transport while also reducing neuroinflammation, the drug works to reverse neurodegeneration in AD, PD and other neurodegenerative diseases.

To view the full webcast, visit https://ibn.fm/qeC3u

To view the full press release, visit https://ibn.fm/SPpXl

Annovis Bio Inc. (NYSE: ANVS) is a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD). Annovis Bio stands out by developing a drug that targets multiple neurotoxic proteins simultaneously, aiming to restore axonal and synaptic activity. This innovative approach aims to treat memory loss and dementia associated with AD and body and brain dysfunction associated with PD, making Annovis a unique player in the neurodegeneration space.

Lead Drug Candidate: Buntanetap

Buntanetap (formerly Posiphen) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This multifaceted inhibition improves synaptic transmission and axonal transport, reduces neuroinflammation, and protects nerve cells from dying. Unlike monoclonal antibody therapies, Buntanetap is an orally available small molecule capable of inhibiting multiple neurotoxic proteins at once, positioning it as a comprehensive solution for neurodegenerative diseases.

In a recent Phase II/III Alzheimer’s study, Buntanetap demonstrated statistically significant efficacy. Patients with early AD showed a significantly higher rate of improvement in ADAS-Cog 11 scores across all treatment doses compared to placebo, with a -3.3 point improvement compared to -0.3 for placebo (p < 0.01). Plasma Tau protein levels also reduced, consistent with previous Phase II biomarker data, further validating Buntanetap’s mechanism of action.

Similarly, in the Phase III study of Buntanetap in patients with early Parkinson’s disease, significant advancements were observed. Topline data results are anticipated in June 2024. Preliminary findings indicate promising results in improving cognitive and motor function, underscoring Buntanetap’s potential as a transformative therapy for Parkinson’s disease.

Market Opportunity

The aging population presents a significant market opportunity, with nearly 7 million Americans currently suffering from Alzheimer’s Disease (AD), a figure projected to rise to almost 13 million by 2050 (Alzheimer’s Association) (Republican Policy Committee). Additionally, approximately 1.2 million people in the U.S. have Parkinson’s Disease (SingleCare).

The economic burden of Alzheimer’s is immense, with care costs expected to reach $360 billion in 2024 and escalate to nearly $1 trillion annually by 2050. The need for effective, comprehensive treatments like Buntanetap is more critical than ever.

Company Highlights

  • Innovative Therapeutic Approach: Annovis Bio uniquely targets multiple neurotoxic proteins, aiming to restore nerve cell health and improve cognitive and motor function in AD and PD patients.
  • Robust Clinical Data: Phase II/III studies show significant improvements in cognitive function and biomarker levels in early AD patients.
  • Groundbreaking Clinical Insights: Preliminary results from Phase II studies indicate significant improvements in motor functions and speed in patients with Parkinson’s Disease (PD).
  • Upcoming Phase III Trials: Plans are underway for an 18-month Phase III trial focusing on biomarker-positive early AD patients, designed to further validate Buntanetap’s disease-modifying potential.
  • Capital Efficiency: Annovis Bio is capital-efficient, with zero debt and multiple global patents extending into the 2040s.

Management Team

Maria L. Maccecchini, Ph.D., Founder, President, CEO, and Executive Board Member, founded Annovis Bio in May 2008 with the mission to develop better therapeutics for Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. She has previously been a partner and director at two angel groups, Robin Hood Ventures and MidAtlantic Angel Group, and founded Symphony Pharmaceuticals/Annovis, which was sold to Transgenomic in 2001. Her extensive experience includes roles such as General Manager at Bachem Bioscience and Head of Molecular Biology at Mallinckrodt. Dr. Maccecchini holds a Ph.D. in biochemistry from the Biocenter of Basel, with postdoctoral work at Caltech and the Roche Institute of Immunology.

Cheng Fang, Ph.D., Senior VP of Research and Development, is an accomplished neuroscientist with two decades of experience in neurodegenerative diseases. She has a successful track record of scientific publications and contributions, coupled with extensive pre-clinical and clinical development experience. Dr. Fang has been instrumental in advancing the understanding of neurodegenerative disease mechanisms and developing therapeutic strategies.

Michael Christie, Ph.D., VP of Process Chemistry, has over 40 years of experience in the pharmaceutical industry, focusing on process chemistry R&D, pilot plant production, and GMP operations. He has held senior management positions at companies such as SmithKline, Rhodia, Teva, and Cephalon, and founded a contract process R&D service company, which was later acquired by ChiRex. Dr. Christie is co-author or co-inventor on several publications and patents. He earned his BS in chemistry from the University of Michigan and his doctorate from MIT.

Melissa Gaines, Senior VP of Clinical Operations, is an accomplished clinical research professional with over 20 years of experience across academia, contract research organizations, and pharmaceutical companies. She has proven abilities in monitoring and managing Phase I to IV clinical trials, specializing in CNS disorders and extending to a broad range of therapeutic indications. Her CNS experience spans from small Phase I and II studies to large global Phase III trials in Alzheimer’s disease, Parkinson’s disease, sleep disorders, and various psychiatric diseases in both adult and pediatric populations. In her current role, she oversees and supports all clinical project activities, driving operational success and ensuring high-quality clinical outcomes.

Learn more about the Annovis Bio team on LinkedIn.

Annovis Bio Inc. (NYSE: ANVS), closed Monday's trading session at $6.5, up 5.3485%, on 158,723 volume. The average volume for the last 3 months is 2.244M and the stock's 52-week low/high is $4.79/$22.49.

Recent News

Longeveron Inc. (NASDAQ: LGVN)

The QualityStocks Daily Newsletter would like to spotlight Longeveron Inc. (NASDAQ: LGVN) .

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines, will be presenting at the Emerging Growth Virtual Conference this week. The two-day event is scheduled for June 12–13, 2024. Longeveron's presentation is slated to begin at 1:45 p.m. ET on Wednesday, June 12. According to the announcement, anyone interested can view the presentation on the company's website at that time. In addition, an archived version of the presentation will be available on the company website following the conference; the presentation will be available for approximately six months.

To view the presentation, visit https://ibn.fm/Xzkfb

To view the full press release, visit https://ibn.fm/tzeYQ

Longeveron Inc. (NASDAQ: LGVN) is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. The Company’s research and therapies are aimed at improving the outcome of infants born with a life-threatening heart condition, as well as improving the healthspan for the aging population – the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging, with function and ability to perform activities of daily living.

Longeveron is involved in clinical trials in the following indications: Hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty.

The Company’s philosophy revolves around the idea that regenerative medicine may hold the potential to improve certain rare medical conditions and contribute to healthy aging. While there has been a remarkable rise in life expectancy over the last century due to medical and public health advancements, this increase in longevity has not been paralleled by the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging.

Longeveron’s lead investigational product is Lomecel-B™, an allogeneic Medicinal Signaling Cell therapy product isolated from the bone marrow of young, healthy adult donors. As humans age, they experience a decrease in immune system function, a decline in blood vessel functioning, chronic inflammation, and other issues. Clinical data has suggested that Lomecel-B™ may address these conditions through multiple mechanisms of action (MOA) that simultaneously target key aging-related processes.

The Company is headquartered in Miami, Florida.

Lomecel-B™

Lomecel-B™ is being evaluated in multiple clinical trials for aging-related chronic diseases and other life-threatening conditions under U.S. FDA-approved Investigational New Drug applications. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas.

The drug is made from special living cells called Medicinal Signaling Cells (MSCs) that are isolated from fresh bone marrow tissue that has been donated by adult donors aged 18 to 45. Once the MSCs have been isolated from the fresh bone marrow through a careful selection process, the cells are culture-expanded (allowed to replicate under controlled laboratory conditions) into the billions using specialized techniques and processes. After a specific number of expansion cycles, called “passages,” the cells are harvested, separated into specific doses (e.g., 50 million cells), and cryopreserved until future use.

These cells have been shown to have characteristics that allow them to be transplanted from a donor to host without triggering a harmful immune response in the recipient, and they can be administered on an outpatient basis in as little as 40 minutes after thawing. Because of these characteristics, Lomecel-B™ is considered an “off-the-shelf” product.

In some trials, such as for Alzheimer’s disease and Aging-related Frailty, Lomecel-B™ is administered via peripheral intravenous infusion, while, in the Company’s HLHS trial, Lomecel-B™ is administered via direct injection into the heart tissue.

Market Opportunity

Longeveron estimates the potential market size for Lomecel-B™ in the treatment of HLHS to be up to $1 billion annually, globally.

U.S. patients suffering from Aging-related Frailty are estimated using U.S. Census Bureau statistics to be approximately 8.1 million. That population potentially represents a market for Lomecel-B™ of between $4 billion and $8 billion globally per year, according to Company estimates.

Additionally, the Alzheimer’s Association puts the number of Americans with that disease at 5.1 million, highlighting another potentially addressable market for Lomecel-B™, that’s worth $5 billion to $10 billion annually.

Management Team

Wa’el Hashad is CEO of Longeveron. He has more than 35 years of experience in the pharmaceutical and biotech industries. He has launched several successful brands in the U.S. and worldwide markets. Prior to joining Longeveron, he was president and CEO of Avanir Pharmaceuticals. Before Avanir, he was the chief commercial officer of Seres Therapeutics. He also has held senior leadership positions at Amgen, Boehringer Ingelheim, and Eli Lilly and Company. He holds a bachelor’s degree in pharmacy from Cairo University and an MBA from the University of Akron.

Joshua M. Hare, M.D., FACC, FAHA, is Co-Founder, Chief Science Officer and Chairman of Longeveron. He is a double board-certified cardiologist and is the founding director of the Interdisciplinary Stem Cell Institute at the University of Miami’s Miller School of Medicine. He is a recipient of the Paul Beeson Physician Faculty Scholar in Aging Research Award and is an elected member of the American Association of Physicians and The American Society for Clinical Investigation. He is also an elected Fellow of the American Heart Association. He received a bachelor’s degree from the University of Pennsylvania and his M.D. from The Johns Hopkins University School of Medicine.

Lisa Locklear is CFO at Longeveron. She previously served as the senior vice president and CFO for Avanir Pharmaceuticals. Prior to Avanir, she held senior financial roles at GSN Games, CoreLogic, Ingram Micro, the Walt Disney Company, and Price Waterhouse, with assignments in Paris and London. She holds a bachelor’s degree in plant science from the University of California, Davis, and an MBA from the University of California, Irvine. She is a licensed CPA (inactive) and is a member of the American Institute of Certified Public Accountants, the California Society of CPAs, and Financial Executives International.

Dr. Nataliya Agafonova, M.D., is the Chief Medical Officer at Longeveron. She previously served as clinical development lead, senior medical director, and product development chair at Otsuka Pharmaceuticals. Before that, she was the clinical development lead and senior medical director at Bristol-Myers Squibb. She previously held senior leadership positions at Ardea Bioscience, Biogen, Amgen, and Genzyme Corporation. She earned an M.D. from the Ukrainian National Medical University and completed her internal medicine residency at Kharkov State University Hospital in Ukraine.

Certain statements in this corporate profile that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “believe,” “expects,” “may,” “looks to,” “will,” “should,” “plan,” “intend,” “on condition,” “target,” “see,” “potential,” “estimates,” “preliminary,” or “anticipates” or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, statements regarding the offer and sale of securities, the terms of the offering, about the ability of Longeveron’s clinical trials to demonstrate safety and efficacy of the Company’s product candidates, and other positive results; the timing and focus of the Company’s ongoing and future preclinical studies and clinical trials and the reporting of data from those studies and trials; the size of the market opportunity for the Company’s product candidates, including its estimates of the number of patients who suffer from the diseases being targeted; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of the Company’s product candidates; the Company’s ability to obtain and maintain regulatory approval of its product candidates in the U.S., Japan and other jurisdictions; the Company’s plans relating to the further development of its product candidates, including additional disease states or indications it may pursue; the Company’s plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and its ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and the Company’s ability to attract and retain such personnel; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s need to raise additional capital, and the difficulties it may face in obtaining access to capital, and the dilutive impact it may have on its investors; the Company’s financial performance and ability to continue as a going concern, and the period over which it estimates its existing cash and cash equivalents will be sufficient to fund its future operating expenses and capital expenditure requirements. Additionally, Longeveron makes no assurance that any public offering of its securities as described herein will occur on the timelines, in the manner or on the terms anticipated due to numerous factors. Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 14, 2023 and its Quarterly Report on Form 10-Q for the second quarter of 2023 filed with the SEC on August 11, 2023. The forward-looking statements contained in this corporate profile are made as of the date of this corporate profile, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor Contact
Mike Moyer
LifeSci Advisors
Tel: 617-308-4306
Email: mmoyer@lifesciadvisors.com

Date prepared: August 31, 2023

Longeveron Inc. (NASDAQ: LGVN), closed Monday's trading session at $1.06, up 1.9231%, on 166,482 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $22.49/$.

Recent News

Clene Inc. (NASDAQ: CLNN)

The QualityStocks Daily Newsletter would like to spotlight Clene Inc. (NASDAQ: CLNN).

new report has called attention to the need to increase investment in multiple sclerosis (MS) research and boost awareness of the illness. The report, which was released on World Multiple Sclerosis Day, was produced by MS Australia. Currently, more than 30,000 Australians live with multiple sclerosis. This is a chronic illness that affects the spinal cord and brain. Researchers have observed that the number of individuals being diagnosed with this condition has been growing at an alarming rate. Monash University's Vilija Jokubaitis, an associate professor from the Department of Neuroscience, is positive that breakthroughs in earlier diagnosis are possible with more financial support for research on the condition, better resources and MS biobanks. Jokubaitis explained that more investment in research will back efforts to discover more accurate biomarkers which are specific to the condition, noting that these biomarkers may be present in cerebral spinal fluid or blood. Enterprises such as Clene Inc. (NASDAQ: CLNN), which are devoting considerable resources towards developing effective ways to protect mitochondria health and thereby manage neurodegenerative ailments such as MS, can also help to drive greater awareness of this condition and the available ways of treating it.

Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Its lead drug candidate is CNM-Au8®, an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.

CNM-Au8

CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

Clene Inc. (NASDAQ: CLNN), closed Monday's trading session at $0.432, up 16.1915%, on 1,553,518 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.25/$1.09.

Recent News

Emperor Metals Inc. (CSE: AUOZ) (FRA:9NH) (OTCQB: EMAUF)

The QualityStocks Daily Newsletter would like to spotlight Emperor Metals Inc. (CSE: AUOZ) (FRA:9NH) (OTCQB: EMAUF).

Emperor Metals' 8,000 m drill program will focus on the open pit concept revealed during last year's program

Both high-grade resources of 5.8 g/t Au over 10.85 m and lower-grade bulk tonnage of 1.69 g/t Au over 25 m were intercepted in 2023

The company intends to continue leveraging its advanced artificial intelligence models to guide targeting efforts for the upcoming drill season

The Duquesne West Gold Property hosts a historical inferred mineral resource estimate of 727,000 ounces of gold at a grade of 5.42 g/t and an average thickness of 5.71 meters in 4.171 million tonnes* (see note at bottom)

Emperor Metals (CSE: AUOZ) (OTCQB: EMAUF) (FRA: 9NH), an advanced stage gold exploration company, has officially resumed drilling at its flagship Duquesne West Gold Property, located within the historic Duparquet gold mining camp in the Superior Province's southern part of the Abitibi Greenstone Belt of Rouyn-Noranda, Quebec. The 8,000 m drill program at the Duquesne West Gold Project follows up on the company's initial drill campaign in 2023, which revealed a significant open pit concept above a high-grade gold deposit (https://ibn.fm/mXzJf).

Emperor Metals Inc. (CSE: AUOZ) (FRA:9NH) (OTCQB: EMAUF) is an advanced stage gold exploration company focused on proving and developing the substantial resource potential of its flagship Duquesne West Gold Project located in the Tier 1 district of the Southern Abitibi Greenstone belt of Rouyn-Noranda, Quebec. The Project has a 2011 historical mineral resource estimate of 727,000 ounces of Au at 5.42 g/t and an average thickness of 5.71 m*.

In 2023, with the use of AI (Artificial Intelligence), Emperor Metals created the first ever 3D mineralized and geological model, which illuminated the potential to add significant ounces to this deposit. Using these models, Emperor’s had a very successful 2023 drilling campaign of 8,579 m. In addition to laterally extending high grade zones by intercepting grades of 15.8 g/t Au over 10.8 meters, Emperor encountered intercepts of lower grade bulk tonnage in the host rocks (1.69 g/t Au over 25 m). This led to envisioning a different strategy of exploration and the revelation that a conceptual open-pit potentially overlies this high-grade gold deposit. Historic core sampling began (2,500 m) for discovering overlooked lower grade gold in the host rock around the high-grade lenses. Lower grade bulk tonnage gold improves the open-pit economics by reducing stripping ratios and adding overlooked incremental ounces for open pit mining.

Emperor Metals is set to begin a fully funded Phase II 8,000 m drilling program in May 2024. The company also plans on assaying an additional 8,000 m of historic core within the open pit model. Emperor is working toward producing an updated NI 43-101 Mineral Resource Estimate by Q1 2025.

The company is led by a dynamic group of resource sector professionals who have a strong record of success in evaluating and advancing mining projects from exploration through to production, attracting capital and overcoming adversity to deliver exceptional shareholder value.

Project

Emperor Metals has an option to earn 100% ownership of the Duquesne West Gold Project, a mineral claim package comprising 38 claims covering approximately 1,389 ha (3,432 acres) in Quebec.

The Duquesne West Gold Property is located 32 kilometers northwest of the city of Rouyn-Noranda and 10 kilometers east of the town of Duparquet. The property lies within the historic Duparquet gold mining camp in the southern portion of the Abitibi Greenstone Belt in the Superior Province.

Emperor is targeting the potential multimillion-ounce resource in a combination of conceptual open pit and underground mining scenarios. A Phase I drill campaign and historical core sampling program was completed in 2023, which included resource confirmation and exploration drilling, focusing on delineating and growing the resource toward development.

The property hosts a historical inferred mineral resource estimate of 727,000 ounces of gold at a grade of 5.42 grams per ton (g/t) and average stope thickness of 5.71 m. The mineral resource estimate predates modern Canadian Institute of Mining guidelines, and a Qualified Person on behalf of Emperor Metals has not reviewed or verified the mineral resource estimate. Therefore, it is considered historical in nature and is reported solely to provide an indication of the magnitude of mineralization that could be present on the property. The gold system remains open for resource identification and expansion.

Reinterpretation of the existing geological model was created using artificial intelligence and machine learning. This AI model shows the opportunity for additional discovery of ounces by revealing gold trends unknown to previous workers and the potential to expand the resource along significant gold-endowed structural zones. Multiple scenarios exist to expand additional resources, which include:

  • Underground High-Grade Gold
  • Open Pit Bulk Tonnage Gold
  • Underground Bulk Tonnage Gold

The Duquesne West-Ottoman property straddles the Porcupine-Destor gold localizing fault several kilometers east of the town of Duparquet. A number of previous drill campaigns have outlined an inferred resource of 4.17 million tons grading 5.42 g/t of gold (cut) or 6.36 g/t (uncut), as reported in the NI 43-101 report titled “Technical Report and Mineral Resource Estimate Update for the Duquesne-Ottoman Property, Quebec, Canada.”

Emperor Metals is funded for an 8,000-meter drilling program focusing primarily on adding ounces to the current resource within and lateral to the open pit model. An additional 8,000 m of historical core sampling and assaying is included in the budget to help build incremental ounces in the open-pit environment.

Market Opportunity

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, to be worth nearly $5 trillion.

The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth. This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council.

In May 2024, the market price of gold was approximately $2,340 per ounce.

Management Team

John Florek, P.Geol., is President, CEO and Director of Emperor Metals. He has more than 35 years of technical and senior management experience with major and junior mining companies, including roles as founder, vice president and director. He has helped identify and develop significant asset value for mines and exploration projects from grass roots through development. He has worked for several major mineral producers, including BHP, Placer Dome, Barrick, Teck and Detour Gold/Kirkland Lake Gold/Agnico Eagle.

Sean Mager is CFO and Director of Emperor Metals. He has worked more than 30 years in the mining sector, including extensive experience in corporate development, stakeholder relations, regulatory, financial and operations.

Alex Horsley is Head of Corporate Development and Director of Emperor Metals. He has more than 20 years of experience in the mining sector and capital markets with a focus on finance, marketing, management, corporate development and communications. He is founder and former CEO of Emperor Metals. He has assisted in raising more than C$40 million for exploration and development mining companies.

*Power-Fardy and Breede, 2011. The Mineral Resource Estimate (MRE) constructed in 2011 is considered historical in nature as it was constructed prior to the most recent Canadian Institute of Mining and Metallurgy (CIM) standards (2014) and guidelines (2019) for mineral resources. In addition, the economic factors used to demonstrate reasonable prospects of eventual economic extraction for the MRE have changed since 2011. A qualified person has not done sufficient work to consider the MRE as current. Emperor is not treating the historical MRE as current. The reader is cautioned not to treat it, or any part of it, as a current MRE.

Emperor Metals Inc. (OTCQB: EMAUF), closed Monday's trading session at $0.095, up 2.7582%, on 26,075 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0597/$0.14505.

Recent News

ECGI Holdings Inc. (OTC: ECGI)

The QualityStocks Daily Newsletter would like to spotlight ECGI Holdings Inc. (OTC: ECGI).

ECGI is implementing several prudent measures to create a stronger foundation for pursuing new strategic ventures and growth opportunities

The company recently announced an agreement to convert $2 million of debt into equity, with conversion expected to be completed during Q4 of its fiscal year

ECGI has previously announced the reduction of over $1.5 million in liabilities, a reduction of over $350,000 in convertible notes payable and accrued interest, and an improvement in total stockholders' deficit totaling over $1 million

The company is determined to position itself to aggressively identify and capitalize on growth opportunities that align with its business objectives

ECGI Holdings (OTC: ECGI), a diversified holding company with a distinctive portfolio encompassing viticulture and luxury fashion, recently announced an agreement to convert $2 million of debt into equity. The agreement, anchored in section 3(a)(10) of the Securities Act of 1933, is a significant milestone in the company's ongoing efforts to enhance financial stability in pursuit of significant market opportunities. The debt-to-equity conversion is set to be completed during the ECGI's fiscal fourth quarter, ending August 31, 2024 (https://ibn.fm/kTWFt).

ECGI Holdings Inc. (OTC: ECGI) is a diversified holding company with a distinctive portfolio encompassing viticulture and luxury fashion. The company owns and manages a five-acre vineyard in Lake County, California, specializing in cultivating the Petite Sirah varietal, known for its bold and rich character, aligning with the growing demand for unique and high-quality wine experiences.

In the fashion sector, ECGI has strategically invested in Pacific Saddlery, a premier manufacturer and retailer of luxury equestrian tack, apparel and accessories. This unique blend of wine and fashion investments reflects ECGI Holdings’ commitment to delivering sophistication and innovation across diverse markets, positioning the company as a distinctive player in the intersection of technology, viticulture and luxury lifestyle.

Moving forward, ECGI Holdings is focused on identifying and capitalizing on growth opportunities that align with the company’s business objectives and continuing to improve its financial structure. In 2024, ECGI Holdings was approved by Evolve — a distinguished name in vacation rental management. This partnership will transform the company’s 40-acre Lake County property into a luxurious short-term rental destination aptly named Vintner’s Caldera Ranch.

ECGI Holdings is excited about the possibilities that Vintner’s Caldera Ranch creates for shareholders and looks forward to further developments poised to unlock the value of other underutilized assets. The company believes that it is laying a solid foundation for sustained success and profitability in the years to come.

ECGI Holdings is headquartered in Irvine, California.

Operational Philosophy

ECGI Holdings has embarked on an ambitious new vision and strategic direction to build and nurture luxury brands that resonate with its core values and market aspirations. Its joint venture with Pacific Saddlery epitomizes ECGI Holdings’ strategic shift toward luxury branding, leveraging Pacific Saddlery’s tangible and established market presence in equestrian products.

This transition will also allow ECGI Holdings to explore new pathways to monetize its underutilized assets, including the company’s vineyard. A key highlight of the company’s future outlook is the debut of Pacific Saddlery’s new mobile retail boutique at specific equestrian events in 2024. This innovative venture represents a significant step in ECGI Holdings’ strategy to enhance brand visibility and engage directly with the company’s target market.

In addition, the Vintner’s Caldera Ranch development marks a significant step in advancing the company’s strategy to revitalize and leverage underutilized assets. Vintner’s Caldera Ranch is set against the backdrop of Lake County’s breathtaking scenery, offering an exclusive getaway experience that blends natural beauty with luxury. Choosing Evolve is a strategic move to ensure that Vintner’s Caldera Ranch not only meets but exceeds the high standards of service that luxury guests expect.

Evolve’s expertise in maximizing rental potential and delivering exceptional guest experiences is crucial to the company’s vision of making Vintner’s Caldera Ranch a preferred choice for discerning travelers. With this venture, ECGI Holdings is not only expanding its footprint within the luxury rental marketplace, but also contributing to the local economy and enhancing the appeal of Lake County as a tourist destination.

The company’s focus remains steadfast on strategic growth, operational excellence and customer satisfaction.

Market Outlook

A report from Grand View Research, a global market research and consulting company, estimated the value of the worldwide luxury brands market at $366.23 billion in 2023 and projects the market to grow to a value of $580.43 billion by 2030, achieving a CAGR of 6.8% over the forecast period.

Rising disposable income and wealth in various regions of the world, particularly in emerging markets such as China and India, have propelled the growth of the market, according to the report.

Younger consumers, such as millennials and Generation Z, are increasingly entering the luxury market, driving demand for more contemporary and experiential luxury offerings. The rise of social media and influencer marketing has greatly impacted the visibility and desirability of luxury products, the report states.

Management Team

Jamie Steigerwald is CEO of ECGI Holdings, Inc. He is a successful entrepreneur with over 30 years of experience. Most recently, he was COO of Sugarmade Inc. (OTC: SGMD), a California cannabis real estate, cultivation, manufacturing and services company. He is the owner of SwiftLead, an Orange County web marketing, design and development company. He previously was COO for First USA Home Loans, a retail mortgage lender, and co-founder and President of SwiftLead Software, a mortgage lead tracking system.

Nick Collins is CEO at Pacific Saddlery. He brings over 25 years of expertise in equestrian luxury goods. He previously founded Rolling Meadows and created the Allon Equestrian and Renard et Cheval apparel brands. He was instrumental in creating and launching Kaval.com, an online equestrian apparel and accessories site.

ECGI Holdings Inc. (OTC: ECGI), closed Monday's trading session at $0.0022, up 4.7619%, on 722,783 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0016/$0.0185.

Recent News

Software Effective Solutions Corp. (OTC: SFWJ)

The QualityStocks Daily Newsletter would like to spotlight Software Effective Solutions Corp. (OTC: SFWJ).

Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ), a leading entity in the cannabis and agricultural technology sectors, is beginning its first expansion phase and is reporting on its strategic initiative. According to the announcement, through careful and deliberate planning and foresight, MedCana is reporting the allocation of an additional two hectares dedicated to production. Calling the move "pivotal," the company noted that MedCana management is committed to meeting escalating market demands and fortifying the company's operational capabilities. In addition, the report noted that MedCana and its majority-held subsidiary, Eko2o S.A.S, have achieved a 35% reduction in construction costs associated with greenhouses and irrigation systems. This "significant milestone in cost optimization" was reached through innovative strategies and collaborative efforts between the two entities and represents the company's focus on being an industry leader, achieving operational efficiency and following sustainable practices. "This expansion marks a significant milestone in our journey," said MedCana CEO Jose Gabriel Diaz in the press release. "We are committed to driving value for our stakeholders while embracing sustainable growth strategies."

To view the full press release, visit https://ibn.fm/bAWM5

Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) is a global infrastructure and holding company in the cannabis industry. MedCana currently has five companies focused on pharmaceutical cannabis production, as well a software company focused on managing processes for plant-to-patient operations. The recent acquisition of an irrigation and greenhouse technology company has rounded out MedCana’s portfolio of holdings.

MedCana’s focus is on developing clients and companies in Latin America, initially in Colombia, and partnerships with laboratories, research facilities and hospitals throughout the world. MedCana is building the technology, laboratories, growing facilities and scientific teams to provide premium pharmaceutical-grade cannabis extracts to the world.

MedCana’s goal is to be the world’s premier resource for pharmaceutical cannabis products. The company believes its advantage is its global view and reach. From initial cultivation to final product, MedCana aims to help partners produce pharmaceutical CBD and other extracts that will have no equal.

The company’s mission is to utilize its technology to partner with and develop companies that provide premium pharmaceutical-grade cannabis extracts with absolute integrity, sustainability and social responsibility. MedCana’s team of pharmaceutical scientists includes some of the most respected chemists in the world. They aim to ensure that the company’s customers and partners create premium cannabis extracts that meet the growing worldwide demand. MedCana’s software is designed to ensure traceability and quality from seed to finished product.

MedCana is headquartered in Austin, Texas, with offices in Colombia.

Production

MedCana announced in May 2023 the beginning of full-scale production of non-THC cannabis for export to Europe in response to high demand in that market. This expansion comes after the successful completion of full crop cycle testing and infrastructure development at production sites in Columbia.

The recent acquisition of the assets of Tokan Corp., a software company focused on creating an enterprise resource planning (ERP) platform for the cannabis industry, and Eko2O S.A.S., a greenhouse and irrigation engineering company, has positioned MedCana for explosive growth in the region.

As a MedCana subsidiary, Eko2O SA will increase the company’s revenue potential in Central and South America. The subsidiary specializes in the construction and distribution of greenhouses and sophisticated irrigation platforms. A positive outlook has resulted from the company’s expansion as it investigates new opportunities for greenhouse and irrigation system installations in Panama and Uruguay. These opportunities are expected to accelerate Eko2O’s development and strengthen its position as a top supplier of innovative agricultural solutions in cannabis and other sectors that are quickly moving to high technology agricultural production.

In addition, MedCana has started talks with the government in Argentina about possible incentives for beginning operations in that country as part of its ongoing worldwide development strategy. Support from the Argentinean government and the start of new operations there would greatly increase MedCana’s market share in Latin America and solidify the company’s position as the market leader in the cannabis industry.

Market Opportunity

According to a report by Grand View Research, a San Francisco-based market research and consulting company, the global cannabis extract market was valued at $3.5 billion in 2022 and is expected to expand at a CAGR of 20% from 2023 to 2030 to be worth more than $15 billion.

Growing demand for cannabis extracts, including oils and tinctures, and the increased legalization of marijuana for the treatment of different chronic ailments like arthritis, Alzheimer’s, anxiety and cancer are driving the expansion of the industry. The marijuana derivative industry is flourishing due to a greater understanding of its various medical benefits.

Management Team

Jose Gabriel Diaz is CEO of MedCana. He has successfully built, grown and sold multiple telecom companies. He was senior vice president of sales at IP Communications, a national high-speed data provider. He also founded Reallinx, a national data carrier later sold to GTT Communications. Additionally, he is currently president of the A.E.M. Business and Entrepreneurship Association in Austin, Texas.

Claudio Jiménez Cartagena, QF, Ph.D. is Chief Scientific Officer at MedCana. He joined MedCana after working with Sosteli Pharma as Technical Director and serving as a director consultant for the Corporation for Agricultural Industrial Development at the University of Antioquia in Colombia. Before that, he worked as the scientific director at the Institute of Food Science & Technology. He holds a bachelor’s degree in pharmaceutical chemistry, a master’s degree in basic biomedical sciences and a doctoral degree in Environmental Engineering from the University of Antioquia.

Julián Alberto Londoño Londoño, Ph.D., is Senior Vice President of Operations at MedCana. He previously served as general manager for the Corporation for Agricultural Industrial Development, and as Chief Scientific Officer at Sosteli Pharma in the Resource Management Department. He has developed multiple U.S. patents, and recently served as senior advisor to the Secretariat of Agriculture Development for the Government of Antioquia. He holds a doctorate in Chemical Sciences from the University of Antioquia.

Software Effective Solutions Corp. (OTC: SFWJ), closed Monday's trading session at $0.05, even for the day, on 1 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.000001/$0.09.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

CARB certification is awarded to vehicle manufacturers that meet specific emissions standards in compliance with CARB regulations

CARB is charged with protecting public from harmful effects of air pollution, developing programs and actions to fight climate change

"Having both our Class 1 and Class 3 commercial EVs now CARB and EPA certified will continue to drive sales in all states across America," says Mullen CEO

With environmental concerns becoming an increasing priority, more states, companies, and consumers are paying attention to — and prioritizing — environmentally friendly products and practices. Mullen Automotive (NASDAQ: MULN), an emerging EV manufacturer, shares this commitment to being environmentally responsible. To underscore this commitment, the company announced that its Mullen THREE, an all-electric Class 3 low cab forward chassis truck, has received certification from the California Air Resources Board ("CARB") (https://ibn.fm/PqLr8).

Mullen Automotive (NASDAQ: MULN), an electric vehicle ("EV") manufacturer, today announced the addition of zero-emissions commercial vehicle dealership, Eco Auto, a Boston, Massachusetts-area dedicated EV dealer. As Mullen's newest franchise dealer, Eco Auto will cover national fleet opportunities for the company's full line of commercial electric vehicles with particular focus on the regional New England area. According to the announcement, Eco Auto's initial vehicle order includes 10 Mullen ONE, Class 1 EV cargo vans, and 3 Mullen THREE, Class 3 EV cab forward EV trucks. "The New England area is a key Northeast hub for commercial fleet companies and one we are excited to enter," said David Michery, CEO and chairman of Mullen Automotive. "Eco Auto brings a wealth of frontline retail experience, a strong dedication to EVs, and is a great partner for us to align with."

To view the full press release, visit https://ibn.fm/xYX1V

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Monday's trading session at $2.83, off by 1.049%, on 1,792,022 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.3565/$382.05.

Recent News

Correlate Energy Corp. (OTCQB: CIPI)

The QualityStocks Daily Newsletter would like to spotlight Correlate Energy Corp. (OTCQB: CIPI).

China has commissioned a worldwide, record-setting solar energy plant. The facility has a capacity of 5,000 MW and can generate at least 6,000G Wh annually. This is more than enough to provide the energy needs of entire countries such as  Luxembourg. This giant plant is found in Xinjiang, a region known for its desert climate. The power plant sprawls over a land mass equal to 200,000 hectares and was set up by Power China. China has set a goal to become carbon-neutral during or before 2060. Predictions indicate that before 2025 comes round, China could ramp up its clean-energy capacity to five times what it currently is, and that could help the country slash its worldwide Co2 emissions share to 22% from its current 33%. As more of these large clean-energy projects come online around the world, more entities such as Correlate Energy Corp. (OTCQB: CIPI) will be needed to develop cost-effective systems through which that energy can be distributed to the target users.

Correlate Energy Corp. (OTCQB: CIPI) is a publicly-traded company strategically positioned to capitalize on America’s unstoppable trend toward decentralized energy generation.

The energy grid in the U.S. is insufficient for the booming clean energy trend, and current infrastructure is limiting green energy distribution. Constructing the needed infrastructure to address this demand imbalance will cost billions and be far too slow, positioning decentralized systems, like those on offer from Correlate, in a key position for heightened demand.

Correlate has identified several key economic drivers powering the decentralized energy trend, including:

  1. Real Cost Savings – Customer pays zero money down and gets an instant electrical price discount to current rates.
  2. Massive Project Investment Funding – The International Energy Agency estimates that over one billion dollars per day will be invested in solar energy in 2023.
  3. Consistent Long-Term Incentives – The Inflation Reduction Act is a game-changer, supercharging renewables with $1.2 trillion in tax credits for 10 years of market support.
  4. Robust Customer Demand – Wood Mackenzie expects the U.S. solar industry to nearly triple in size over the next five years.

Correlate’s team of multi-decade experts who have worked with renowned global brands are positioning the company to make the most of this opportunity while consolidating a fragmented industry. Collectively, the team has developed, financed and deployed over $2 billion in clean energy projects to date.

Three-Pronged Strategy

Correlate is leveraging a three-pronged strategy aimed at driving shareholder value:

  1. Sell – Correlate seeks to finance, develop and profitably sell localized clean energy solutions and microgrids to industrial, commercial and residential customers.
  2. Retain – Correlate plans to retain ownership of some of these energy systems and thereby realize ongoing, reliable cash flow.
  3. Acquire – Correlate seeks to acquire proven renewable energy companies in order to exponentially grow earnings per share for investors.

This strategy is enhanced by current investment trends. Clean energy earnings are being sought after by investors. In Q4 2022, the median EBITDA multiple for green energy companies was 12.3x, according to Finerva.

Market Outlook

Over the next decade and beyond, renewable energy growth is expected to come primarily via decentralized systems like those offered by Correlate.
The Inflation Reduction Act enacted in late August 2022 is likewise expected to drive growth for the company by providing new tax incentives that reduce costs for clients and/or elevate returns to investors.

Commercial buildings consume more than 35% of the generated electricity in the U.S. and are underperforming in energy efficiency at every level. These buildings waste energy, emit too much carbon and are too costly for owners and occupants, but retrofits are not happening at the rate or scale needed.

In today’s real estate market, portfolio property owners own most commercial buildings, yet most building efficiency work is focused on single buildings, thereby missing the distinct needs of this owner class which are very different from traditional owner-occupiers. The diverse nature of commercial buildings, combined with technology and performance uncertainty, make simple energy optimization initiatives – which could greatly reduce energy use and improve building value – financially unattractive, resulting in slow adoption rates. CIPI’s financial instruments and software breakdown this issue, known as the ‘split incentive’, unlocking the majority of the addressable market.

A key portion of Correlate’s strategy relates to consolidation of what has been a fragmented industry. By uncovering opportunities to improve efficiencies through strategic M&A activities, the company intends to enhance profitability throughout its operations.

Management Team

Todd Michaels is President and CEO of CIPI and founder of Correlate. He formerly served as Vice President for Innovation at SunEdison and Senior Director Distributed Solar at NRG Energy. He founded Correlate in 2015 and has 16 years of experience in the energy industry. He graduated from Indiana University with a B.S. in Computer Information Systems.

Channing Chen is CFO at CIPI and Correlate Inc. and brings over 16 years of experience in the solar industry as a developer, financier, and business unit leader. He has held executive management roles at Solar Power Partners (acquired by NRG Energy), where he was a founding employee, SunEdison, and NRG Energy (NYSE: NRG). Most recently, Mr. Chen was founder and Managing Partner at Breakaway Energy Partners LLC – a distributed energy financing and market-making platform. To date, Mr. Chen and his teams have raised over $1.5 billion in financing across residential, commercial, and utility scale solar and energy storage projects representing over 400 MWs. He holds a B.A. in Environmental Chemistry from the University of California at San Diego and an MBA from the University of Southern California. He is also an advisor and early-stage investor to several startup companies in the renewable energy space.

Dave Bailey is Chief Revenue Officer of Correlate Inc. With over 15 years of executive sales, supply chain management, and energy efficiency experience, he is responsible for ensuring the success of the National Commercial Sales Unit across multiple regional project teams. Mr. Bailey created and launched the Transformation Services team while at Wesco for its multibillion-dollar Distributed Energy Resource division, formerly Westinghouse. His focus was on IoT-enabled efficiency and plant floor automation-based services. Before that, he spent several years in Global Account Sales Management, with GE Supply as a Program Manager, and is a Commercial Leadership Program graduate. Mr. Bailey received his B.S. in Mechanical Engineering from the University of Kentucky.

Jed Freedlander is the company’s Chief Development Officer. He has a background in infrastructure development and investment and a strong legal, commercial and finance acumen. Mr. Freedlander has a proven track record in leading complex public-private partnership (P3) and energy transactions and is instrumental in driving Correlate’s strategic development initiatives.

Roger Baum is Executive VP Operations at Correlate. With over 20 years of experience at Core Construction, he brings to the company a wealth of knowledge and a strong track record in delivering successful commercial construction projects.

Jason Loyet is Director of Solar Energy for Correlate Inc. He is a cleantech executive with over 20 years of experience leading high growth solar energy and software start-ups. Mr. Loyet is a U.S. Department of Energy SunShot Catalyst award winner for his work building the Solar Site Design technology platform. Before joining the solar energy industry in 2005, he founded and sold two software companies in the streaming media (GlobalStreams) and newspaper publishing (MyCapture) industries. Mr. Loyet currently serves as a Member of the Board of Directors for the Tennessee Solar Energy Industry Association (TenneSEIA).

Correlate Energy Corp. (OTCQB: CIPI), closed Monday's trading session at $0.5049, off by 18.872%, on 625 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.4121/$2.35.

Recent News

First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF)

The QualityStocks Daily Newsletter would like to spotlight First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) .

Earlier this month, Microsoft rolled out its Data Center Community Pledge, which is focused on making sure that the company's data center footprint assists in creating benefits in local communities and addressing societal issues. Noelle Walsh, Microsoft VP of cloud operations and innovation, stated during the launch that this was a pledge that the company's data centers would have a positive impact on the communities they serve. This move by the company comes as it commences the building and operation of a worldwide network of advanced data centers, a surge in the adoption of artificial intelligence driving its growth. Walsh added that Microsoft relied on an extensive network of officials, local suppliers, residents and stakeholders to plan, build and operate the facilities, then noted that they acknowledged the importance of supporting communities. In her conclusion, Walsh noted that through partnerships, the company was creating a future that was rooted in environmental sustainability and social responsibility while pioneering new technology. Many more companies such as First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) are increasingly taking measures to mitigate any ESG issues that could result from their operations. This suggests the fight against climate change could show tangible results a lot sooner than analysts initially thought.

First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) is committed to exploring for and providing essential and critical metals, including tellurium, gold, silver, copper and tungsten, for North American markets. This objective is anchored by the company’s Deer Horn tellurium-gold-silver-copper project in British Columbia, Canada, and further enhanced by its property option on the Klondike tellurium-gold prospect located in Colorado, USA.

First Tellurium’s unique business model is to generate revenue and value through mineral discovery, project development, project generation and cooperative access to untapped mineral regions in indigenous territory with sustainable exploration potential.

The company is headquartered in Vancouver, British Columbia.

Tellurium and the Green Energy Revolution

Tellurium has a key role to play in the ongoing green energy revolution. It is widely used in the manufacturing of photovoltaic cells for solar panels.

Despite this utility, ongoing trade tensions between China and the U.S. create implications for both tellurium and the production of cadmium-tellurium solar cells. Earlier this year, China announced plans to restrict exports of critical metals gallium and germanium, both essential for the production of semiconductors. For reference, China produces around 80% of the world’s gallium and approximately 60% of the world’s germanium.

China’s recent trade restrictions amplify the fragility of the North American tellurium supply, as the Asian nation currently produces about 60% of the world’s tellurium. This sustained supply vulnerability is why First Solar, the United States’ largest solar panel producer, set up a worldwide search for tellurium deposits in the mid-2000s.

“In North America alone, our understanding is that First Solar looked at over a hundred tellurium properties,” First Tellurium CEO Tyrone Docherty stated in a news release. “Their number one property by far, which they acquired, was the Colorado Klondike which we now control.”

The U.S. is now looking to secure safe, domestic sources of tellurium and many other critical metals to pre-empt potential shortages. The Biden administration has instituted a stream of policies, particularly the U.S. Inflation Reduction Act, to source solar components from North America and other “friendly” jurisdictions.

As the only junior mining company in the world focused on tellurium exploration, First Tellurium is ahead of the curve in capitalizing on these initiatives to establish strategic, domestic supplies of key resources for solar panel manufacturers.

First Tellurium’s ESG Initiatives

Through its exploration and partnerships with Fenix Advanced Materials, Cheona Metals and IRMA, First Tellurium strives to generate a measurable, beneficial social or environmental impact alongside a financial return. The company conducts a diversified search for metals, working in alliance with indigenous peoples, NGOs, governments and leading metals buyers. First Tellurium believes this is the future of mineral exploration — generating revenue by exploring responsibly and leveraging diverse partnerships.

First Tellurium proudly adheres to, and supports, the principles and rights set out in the United Nations Declaration on the Rights of Indigenous Peoples and, in particular, the fundamental proposition of free, prior and informed consent.

 

Projects

Deer Horn Tellurium-Gold-Silver-Copper Project

Deer Horn is located on 51.33 square kilometers (km) in west-central British Columbia, 36 km south of the prolific Huckleberry copper-molybdenum mine and 135 km southwest of the community of Burns Lake. It is one of few significant tellurium discoveries outside Asia and includes a 2.4 km-long vein system of high-grade gold, silver and tellurium, as well as broader zones of bulk-tonnage gold, silver and tellurium mineralization. The company completed a positive Preliminary Economic Estimate and has begun permitting for a 10,000-tonne bulk sample program to advance the project toward mine feasibility. It is North America’s only silver-gold-tellurium property with an NI 43-101 compliant tellurium resource, and it hosts a number of other mineralized targets and zone containing critical metals such as copper, tungsten and zinc.

First Tellurium owns 50% of the property, with an option to acquire up to a 75% interest. The company has engaged Dias Geophysical of Saskatoon, Saskatchewan, to conduct induced polarization (IP) geophysics on the Deer Horn Project in summer 2023. The program is designed to help develop drill targets for a subsequent drilling program.

Klondike Gold-Tellurium Project

The Klondike property is located in Saguache County, Colorado, southwest of Buena Vista in the state’s historical mining district. The company reports it has engaged Burgex Mining Consultants of Sandy, Utah, to stake additional claims around the Klondike property. The claims have been filed with the Bureau of Land Management.

Klondike demonstrates exceptional tellurium grades. Tellurium, used in high-efficiency cadmium telluride (Cd-Te) solar panels, next-generation lithium-ion batteries and thermoelectric devices to change heat into energy, is an essential element for the world’s transition to green energy.

The Klondike property was a top tellurium prospect owned previously by First Solar Inc., one of the world’s largest solar panel producers. First Solar terminated its worldwide raw materials exploration program in 2012 and sold the property to Colorado Klondike LLC, which optioned the project to First Tellurium. Colorado Klondike, led by First Solar’s former Exploration Manager in North America, is managing the upcoming exploration program.

The Colorado Geological Survey (CGS), in partnership with the Colorado School of Mines, reported on First Solar’s exploration at Klondike in 2015, noting: “Surface sampling by First Solar, Inc. in 2006 found very high tellurium grades of up to 3.3% (33,000 ppm), along with locally high gold grades. Tellurium grades at Klondike were the highest encountered in the company’s nationwide exploration program.”

Market Outlook

First Tellurium in spring 2023 referenced recent forecasts by the International Energy Agency (IEA) pointing to rapid growth in solar photovoltaic (solar PV) deployment worldwide. According to the agency, solar PV installations will generate more power by 2027 than any other energy source, including coal, natural gas and hydro. To meet this demand, consumption of both silver and tellurium, key components of solar panels, is expected to surge in coming years.

Chen Lin, founder of Lin Asset Management, has written in his investment newsletter for clients that solar PV is now the largest industrial usage of silver. He said that in 2022 solar PV production used about 12% of total silver demand, or about 120 million ounces of silver. Lin expects this number to rise dramatically in the coming years, and that is likely to lead to silver supply deficits for decades to come.

Lin points out that solar power is now the cheapest source of energy in many parts of the world and that all forecasts point to dramatic expansion of solar PV in the coming two decades. Conservative estimates forecast 300 gigawatts of solar PV production by 2027, up from the current level of about 200 gigawatts.

Management Team

Tyrone Docherty is President, Director and CEO of First Tellurium Corp. He previously served as President and CEO of Quinto Mining Inc., taking over when it had a market cap of $4 million. With limited resources in a difficult market environment, he raised more than $30 million and advanced Quinto’s Quebec iron ore property to a viable project. Quinto later sold for $175 million, with Quinto management taking shares of the purchaser, Consolidated Thompson Iron Mines, amounting to approximately 20-21% of that company. Consolidated Thompson Iron Mines sold two years later for $4.9 billion, giving the former Quinto team an enterprise value of approximately $1 billion. From 2012 to 2018, Mr. Docherty was Director and Chairman of Mason Graphite Inc. He has worked in the financial and minerals markets for more than 30 years.

Tony Fogarassy, M.Sc. LL.M., is Chairman of First Tellurium Corp. He is a lawyer and a geologist. His extensive legal and technical expertise includes minerals, oil and gas, coal and renewable energy projects and environmental and aboriginal/indigenous law in North America, Africa and Asia. He graduated as gold medalist in geological sciences from the University of British Columbia and in law from the London School of Economics.

First Tellurium Corp. (OTCQB: FSTTF), closed Monday's trading session at $0.0959, off by 6.7121%, on 134,341 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.047785/$0.1108.

Recent News

GEMXX Corp. (OTC: GEMZ)

The QualityStocks Daily Newsletter would like to spotlight GEMXX Corp. (OTC: GEMZ) .

The strategic venture marks a milestone in the company's expansion into the energy sector, demonstrating GEMXX's commitment to diversification and growth

The project will be overseen by Dinesh Kumar Sarraf, the former chairman and managing director of Oil and Natural Gas Corporation Ltd, India's leading exploration and production company

The drilling of the four test wells is set to begin in the coming months, with expected results providing valuable data on the region's oil potential

GEMXX (OTC: GEMZ), a publicly traded exploration company engaged in gold, gemstones, oil, and gas, has announced the signing of a Definitive Agreement with Latin Energy Partners ("LEP") to drill four test wells in a promising geological formation in Latin America. This strategic venture represents a significant milestone in GEMXX's expansion into the energy sector, highlighting the company's dedication to diversification, growth, and enhancing shareholder value. For more information, visit (https://ibn.fm/wW3Jo).

GEMXX Corp. (OTC: GEMZ) is a mine-to-market enterprise specializing in gold, gemstone, and jewelry production. With ownership of mining resources, production facilities, and operational assets, the company maintains control over every aspect of its production process, from gold mining and gemstone extraction to jewelry manufacturing and global distribution.

As a prominent player in the industry, GEMXX stands out as a leading producer of high-quality finished Ammolite jewelry. Notably, it holds the distinction of being the sole public company engaged in Ammolite mining worldwide. In addition to its Ammolite operations, the company is actively involved in gold mining and prides itself on its ability to design and manufacture exquisite jewelry pieces and exceptionally rare, natural fossil decor items for clientele around the globe.

One of GEMXX’s key advantages lies in mining its own gold reserves to be utilized in its jewelry production. This strategic approach provides the company with a cost-saving edge over other producers in the market.

Ammolite is similar to black opal and is a biogenic gem like amber and pearl. It is derived from the fossilized shells of ammonites, a group of extinct marine nautiluses.

GEMXX’s world class gemstone cutters and jewelry designers are continuously leading the Ammolite industry. Its team believes in the company’s philosophy, vision and goals, and works every day to continue to drive the Ammolite industry to the forefront of the gem world.

The company has offices in Las Vegas and Hong Kong.

Projects and Operations

GEMXX has formulated an ambitious growth plan that, while challenging, is deemed attainable. The company’s strategy revolves around bolstering its market share through several key initiatives. Firstly, GEMXX aims to strengthen its position in current markets by nurturing and expanding existing relationships with customers and partners.

Secondly, the company plans to venture into untapped markets strategically. By identifying and targeting new areas, GEMXX seeks to establish a presence in regions that present promising opportunities for growth.

Additionally, GEMXX envisions growth through acquisitions. By considering and integrating key services, distribution networks and retail outlets into its fold, the company aims to consolidate its market position and capitalize on synergies for enhanced success.

To cater to the rising demand for its products, GEMXX has placed a primary focus on increasing gemstone production. The company’s southern properties, situated in Alberta, Canada, hold valuable deposits of rough Ammolite gemstone. By tapping into these resources, GEMXX is poised to meet the demand for its exquisite gemstone products and further fuel its expansion plans.

 

GEMXX possesses significant mineral assets in the form of a Mineral Work Permit covering an 800-acre area and two Ammonite Shell Mineral agreements encompassing 217 acres within the same region. The company’s management effectively operated mines in close proximity to these properties. Moreover, core sampling, along with fossil outcroppings on the riverbanks, confirms a substantial Ammolite resource present in these designated areas.

Both the Mineral Work Permit and the Ammonite Shell Mineral agreements grant GEMXX unrestricted access to all Ammolite resources within their respective demarcations. Notably, the company is not obligated to pay any royalties to third parties, thereby enabling GEMXX to fully capitalize on the potential of these valuable resources.

Furthermore, there are no stringent regulatory conditions that GEMXX must fulfill to gain or retain access to the Ammolite deposits. This freedom of access allows the company to proceed with its mining and production operations unimpeded, providing an advantageous position for future growth and success.

In March 2023, GEMXX made a significant announcement, revealing its acquisition of a 50% ownership stake in Crazy Horse Mining Inc., a Canadian gold mining company with assets situated in the province of British Columbia. As part of this deal, Crazy Horse’s assets, which encompass a 100% interest in two gold projects, called Snow Creek and Rosella Creek, spread across a substantial area exceeding 700 acres, now become part of GEMXX’s portfolio.

Under the terms of this strategic partnership, GEMXX and Crazy Horse will jointly share the expenses related to mining operations on these projects. Additionally, the two companies will share the gold produced from these ventures, leading to a collaborative and mutually beneficial arrangement.

Initial tests conducted on the property, combined with gold already recovered this season, confirm all expectations for the claims and substantiate the company’s estimated extraction target of over 100,000 ounces of easily recoverable gold. To validate and provide a more comprehensive assessment of this estimate, an S-K 1300-compliant Resource Report is scheduled to be conducted during the summer of 2023.

By acquiring this stake in Crazy Horse Mining Inc., GEMXX has positioned itself for further growth in the gold mining sector and is poised to capitalize on cost of goods savings in its jewelry business.

Market Opportunity

Leading independent market research companies such as Data Monitor and GIA estimate the worldwide market for luxury or premium lifestyle products, which include gems and jewelry, at over $90 billion annually and growing. Ammolite sales around the world have seen unprecedented growth over the past 20 years. Worldwide retail sales are now estimated to be over $100 million.

Ammolite jewelry and fossils are featured aboard cruise ships and can be found in specialty shops in almost every cruise port in North America. Asian markets have grown since feng shui master Edward Li called Ammolite the most influential stone of the new millennium, referring to it as the “Seven Color Prosperity Stone.” Home shopping channels in Japan, Australia, France, Germany, the UK, Canada and the U.S. have all featured Ammolite jewelry.

Ammolite and ammonites can also be found on many ecommerce sales platforms, including Amazon, eBay and Etsy. Ammolite is sold around the world in tourist and traditional jewelry markets. The company has established customers in home shopping channels, cruise tourism, jewelry retailers, Asian feng shui markets, Asian retail markets and ecommerce platforms.

Management Team

With over 160 years in Ammolite management, operations, and sales, GEMXX possesses an unparalleled wealth of knowledge and expertise. Its team members have extensive backgrounds in every facet of the Ammolite business, allowing the company to excel in product development, maintain rigorous quality control measures, and maximize profitability. The breadth and depth of the GEMXX team’s experience enable the company to navigate the industry with precision, ensuring that GEMXX remains at the forefront of the Ammolite market. GEMXX leverages its collective wisdom to drive innovation, deliver exceptional products, and optimize business strategies to achieve long-term success.

Jay Maull is Founder, CEO and Chairman of GEMXX. With a career spanning more than three decades, he has been deeply involved in the Ammolite industry, from mining and production to marketing. He has owned and operated the world’s largest Ammolite mine and has delivered exceptional Ammolite products to customers across all continents. He has also established the world’s largest Ammolite ecommerce platform.

Richard Clowater is President of GEMXX. He is a skilled sales and marketing professional with a focus on research, data analysis and strategic planning. He has successfully implemented initiatives to expand markets, boost profits and foster customer loyalty. He has an impressive track record of negotiating sales and contracts worth over $250 million with influential stakeholders, including key purchasing personnel, C-suite executives and government entities at all levels.

Tom Dryden is a Vice President of GEMXX and brings a wealth of experience and expertise to the production and marketing of Ammolite, spanning over 30 years. His extensive involvement in the industry has granted him unparalleled knowledge of the Bearpaw Ammonite bearing formations. As a recognized authority in the field, Mr. Dryden’s research and papers on Canadian Ammonites have garnered global recognition, being published worldwide. In his role at GEMXX, Mr. Dryden assumes the responsibility of overseeing the company’s Canadian-based production facilities. 

P. K. Chung is Business Manager Asia at GEMXX. With a track record of over 25 years in Ammolite business management, production and marketing in Asia, she is a recognized authority in the industry. Based in the Hong Kong gem district, she possesses an intricate understanding of the Asian gem and jewelry markets, including market dynamics, consumer preferences and industry trends specific to the region. Her strategic insights and deep connections enable GEMXX to thrive in this influential market.

GEMXX Corp. (OTC: GEMZ), closed Monday's trading session at $0.025, off by 3.1008%, on 10,900 volume. The average volume for the last 3 months is 12,295 and the stock's 52-week low/high is $0.0172/$0.19.

Recent News

Golden Triangle Ventures Inc. (OTC: GTVH)

The QualityStocks Daily Newsletter would like to spotlight Golden Triangle Ventures Inc. (GTVH).

Golden Triangle Ventures Inc. (OTC: GTVH) is a multifaceted consulting company pursuing ventures in the health, entertainment and technology industries, with many additional projects being developed that provide synergistic values to these divisions. The company aims to purchase, acquire and/or joint venture with established entities that management can help assist and develop into unique opportunities.

Additionally, GTVH provides a professional corporate representation service to different companies in these sectors while consulting on a variety of business development objectives. The goods and services represented are driven by innovators who have passion and commitment to these marketplaces.

The company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services. The three points of the Golden Triangle exclusively represent these three sectors in which the company aims to do business.

Health Division – Global Health Services

Global Health Services is a wholly owned subsidiary of Golden Triangle Ventures (operating under its Health Division). Dedicated to the promotion of well-being and natural wellness, the company currently does business in the industrial hemp/CBD industry. Additionally, the company has a vision to promote, market and generate sales for a myriad of products and services which include a full retail line of high-end, all-natural health, wellness and beauty products.

To help achieve this vision, Global Health Services is in the process of further developing an extensive online portal that will support the multiple verticals under the company and provide a one-stop-shop for all of the company’s products and services. Moreover, to support overarching business goals, senior management tirelessly works on acquiring and building an array of profitable assets and projects.

Entertainment Division – Lavish Entertainment

Lavish Entertainment (EpicRaves) is a wholly owned subsidiary of Golden Triangle Ventures under its Entertainment Division. Operating out of Las Vegas, Nevada, the company started doing business in 2017 and was established with a vision of becoming a nationally recognized concert production company. The company currently has more than 30,000 national followers and nearly 100 team members who have helped the company successfully organize some of the most exciting Electronic Dance Music concerts in Las Vegas.

Lavish Entertainment is currently doing business as EpicRaves, which will eventually become a wholly owned subsidiary of Lavish Entertainment as the company expands its business into a variety of other forms of entertainment. The company is currently building a unique virtual reality platform to help expand on its live events, and it is working to acquire a 68,000 sq. ft. event center with a vision to develop one of the most advanced event centers in the world.

Technology Division – HyFrontier Technology

HyFrontier Technologies is a wholly owned subsidiary of Golden Triangle Ventures under its Technology Division. The company owns a patent-pending process and device technology called HyGrO, which is a molecular hydrogen and oxygen delivery system for agriculture. Golden Triangle Ventures is assisting the company in commercializing the HyGrO unit for farm and home use in markets across the globe. HyFrontier Technologies has a mission to improve global crop production efficiency by producing hydrogen and oxygen directly in the water stream.

This technology can be used on any species of plant life in nearly any grow medium. Additionally, the system can be retrofitted to wellheads for large-scale agricultural projects, indoor grow operations and small farms or utilized for a multitude of residential home and garden applications. In-house testing has shown evidence that hydrogen is capable of increasing crop yields by up to 25% and, in many circumstances, a much higher amount. Larger root systems and better overall plant health were also observed by watering plants with the HyGrO unit. Universities and multiple third-party testing facilities are currently working to validate the HyGrO technology, and all preliminary results are extremely positive.

To push the development and commercialization of the technology, management is now in the process of moving the company headquarters from Colorado to Florida, which will transition its operations into a 7,800 sq. ft. state-of-the-art manufacturing facility. The company recently executed a three-year lease with an option to purchase the entire 24,000 sq. ft. building, which will help the business in achieving its ultimate goal of commercializing this technology to the world.

Food & Wine Division – Napa Wine Brands

Napa Wine Brands is a wholly owned subsidiary of Golden Triangle Ventures which is a synergistic business with a mission of providing a world-class portfolio of unique brands birthed from Napa Valley and Sonoma Valley in the heart of California’s Wine Country.

The company has a commitment to manufacture and distribute specialty wines, foods and unique items while tapping into an array of hidden markets in the food and beverage industry. With extensive resources and award-winning products, Napa Wine Brands aims to develop some of the most desirable products in today’s market. Originated by some of the most profound experts in Napa Valley, the company’s vision is to broaden the horizon of a traditional food and wine company by creating a platform different than anything seen in the Northern Hemisphere.

Napa Wine Brands has an array of fully developed products and services that provide value to the other divisions under Golden Triangle Ventures. The company is now preparing the launch of several brands, products and services that are market-ready and will immediately turn into cash-positive businesses. Golden Triangle Ventures will provide a full support system and assist management of Napa Wine Brands in growing this company into another fun, exciting and profitable division of Golden Triangle Ventures.

Recent Updates

  • On May 26, 2021, Golden Triangle announced its acquisition of The Lodge Winery & Olive Oil Co. under the company’s Napa Wine Brands subsidiary. The Lodge Winery & Olive Oil Co. is an established wine brand that produces award-winning wines, olive oils and wine vinegars. “Our marketing team is now ready to launch an in-depth program focused on driving our products into big box stores, smaller retail outlets, online platforms and many other avenues,” Steffan Dalsgaard, CEO of Golden Triangle, stated in a news release announcing the acquisition. “We are working directly with [Napa Wine Brands CEO] Arron [Johnson] and his team to grow their bulk inventory and launch all of these products for the world to enjoy.”
  • On May 20, 2021, Golden Triangle announced its entry into a letter of intent to acquire Sonder Fulfillment LLC, a leader in the industrial hemp and CBD space that is dedicated to driving forward the most powerful and efficacious cannabinoid products in the world. “Over the past two years, our operating partners have compiled a team of the best minds in the industrial hemp industry to create a totally vertical operation from seed to shelf,” Joshua Weaver, CEO of Sonder Fulfillment, stated in a news release announcing the LOI. “This acquisition by Golden Triangle Ventures will fully capitalize our operations and allow us to further expand our product lines and enter into new markets across the globe.”
  • On May 19, 2021, Golden Triangle announced the execution of a formal agreement with Robert “Bo” DuBose to purchase the remaining 49% of HyFrontier Technologies Inc., giving Golden Triangle 100% ownership of the technology company. “This acquisition has been something that Bo and I have been working towards for quite some time and we are both incredibly happy to have this executed,” Dalsgaard stated in a news release announcing the acquisition. “We knew that completing this agreement would show the world that we are both fully committed to our shareholders and the brilliant future of this revolutionary company.”
  • On May 12, 2021, Golden Triangle announced its acquisition of a top tier, professional sound system and formed a partnership with SuperKollider Sound LLC to provide a strategic benefit to the company’s entertainment division under Lavish Entertainment Inc. “We are very excited to acquire this unbelievable sound system,” Dalsgaard stated in a news release announcing the acquisition. “Hennessey Sound Design has always been one of my favorite systems on the market, and the team at SuperKollider Sound are true professionals in this space.”

Management Team

Steffan Dalsgaard is the Founder & Executive Chairman of Golden Triangle. He has a background in business development, with over a decade of experience representing and consulting with dozens of private and public companies. Mr. Dalsgaard consults with companies on all of their corporate objectives while providing a professional and corporate face to their organizations. He has built a strong reputation in the public relations industry and has a mission to work with emerging growth companies that are positioned to become significant businesses in their respective fields.

Robert DuBose is the company’s Chief Innovations Officer & Director and the CEO of HyFrontier Technologies Inc. Mr. DuBose is responsible for the success of the HyGrO product in the agricultural market. His experience in the design and production of hydrogen equipment goes back more than a decade, including PEMFC technologies since 2009 with his company, Aquafuel Inc. Mr. DuBose was raised in the farming and machine shop business, where he learned firsthand how much work and love goes into a successful crop, as well as how elements, which are out of the farmers control, can have adverse effects on finances. His belief that being able to deliver a solution to increase growth, yield, health, stamina of crops and profitability for farmers would be a win-win for all led him to create the HyGrO product.

Stuart Seim is the Chief Development Officer & Director of Golden Triangle. He began his career as an associate professor at the University of Manitoba in the field of outdoor and environmental education after receiving his master’s degree and completing advanced educational studies. Coming from a family with an extensive financial background, Mr. Seim became a stockbroker for major regional financial firm Robert W. Baird. In a short time, he became the Branch Manager for Baird in Minneapolis, Minnesota, while also serving as a Managing Director for Baird. During this time, Mr. Seim also served on the board of an industrial hearing company, which he helped to launch as a new company (The TK Group). Mr. Seim currently resides in Colorado, where he is an advisor to several organizations.

Golden Triangle Ventures Inc. (GTVH), closed Friday's trading session at $10.83, up 4.4359%, on 81,689 volume with 697 trades. The average volume for the last 3 months is 269,609 and the stock's 52-week low/high is $2.33999991/$20.0783996.

Recent News

McEwen Mining Inc. (NYSE: MUX) (TSX: MUX)

The QualityStocks Daily Newsletter would like to spotlight McEwen Mining Inc. (NYSE: MUX) (TSX: MUX).

McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) is an asset rich diversified gold and silver producer in the Americas with a large exposure to copper through its subsidiary, McEwen Copper, owner of the Los Azules copper deposit in Argentina, believed to be the 8th largest undeveloped copper resource in the world.

Led by a management team with a track record of success, MUX owns and operates mines in some of the most prolific gold producing regions of the Americas. The company proactively took cost-saving measures months ago to lower expenses and increase production across its portfolio of gold assets, driving some production costs below industry averages. Gold and copper prices, already in an upswing, are forecast to enter an explosive uptrend over the next couple years. Drawing from its experience, McEwen Mining planned, prepared and laid the groundwork to capitalize on this emerging opportunity.

The company currently holds a Zacks Rank #1 (Strong Buy), placing it in the top 5% of over 4,000 stocks ranked by Zacks, based on trends in earnings estimate revisions and EPS surprises. Seldom is management so aligned with investors’ interests and committed to the company’s success. With a combined investment of over $220 million, CEO Rob McEwen holds a 17% ownership stake in McEwen Mining and a 13% ownership in McEwen Copper. Acclaimed in the mining industry, McEwen founded Goldcorp, where he increased the company’s market capitalization 160 times – from $50 million to over $8 billion. That same vision and tenacity led MUX in creating McEwen Copper.

For McEwen Mining shareholders, beyond the company’s exposure to gold upsurges, its 47.7% stake in McEwen Copper is expected to be a blockbuster, turbocharging MUX by creating the world’s next prolific copper unicorn.

McEwen Copper

With continuous industrial need, new critical demand for copper is rapidly emerging, increasingly driven by the green energy transition. The price of copper rose from a low of about $2 per pound in 2020 to over $4.60 per pound in May 2024, and strong demand is expected to intensify. A study by S&P Global, titled The Future of Copper: Will the Looming Supply Gap Short-circuit the Energy Transition?, projects global copper demand to nearly double over the next decade, from 25 million metric tons today to about 50 million metric tons by 2035. Based on current trends, S&P Global forecasts annual supply shortfalls to reach nearly 10 million metric tons in 2035.

McEwen Mining owns a 47.7% equity stake in McEwen Copper, the holder of a 100% interest in the Los Azules copper project in San Juan, Argentina, which is ranked the 8th largest undeveloped copper deposit in the world. Current copper resources at Los Azules are estimated at 10.9 billion pounds at a grade of 0.40% Cu (Indicated category) and an additional 26.7 billion pounds at a grade of 0.31% Cu (Inferred category). McEwen Copper also owns a copper exploration project in Nevada, USA, called Elder Creek.

In a 2023 Preliminary Economic Assessment (PEA), Los Azules was estimated to have a 27-year life, producing an average of 322 million lbs. of copper cathode annually, at a cash cost of $1.07 per lb. of copper, in the lowest quartile of the copper cost curve. The project could ultimately become an even larger mine with a longer life, since the extent of mineralization has not been fully assessed on the property.

The project’s 2023 PEA presents a distinctly different development strategy from a prior PEA published in 2017. By proposing a heap leach project using solvent extraction-electrowinning instead of the previously detailed mine with a conventional mill and flotation concentrator, McEwen Copper aims to decrease its environmental footprint and reduce permitting risk, albeit with a lower overall copper recovery, slightly higher unit costs and a delay in immediate cashflow due to extended leach cycles.

After securing a $25 million investment from mining giant Rio Tinto’s technology arm, Nuton LLC, McEwen Copper closed its non-brokered, private placement offering of $82 million in August 2022. Shortly after, in February 2023, Nuton agreed to invest an additional $30 million into McEwen Copper, and in October 2023, Nuton once again expanded its stake, investing an additional $10 million to bring its ownership position in McEwen Copper to 14.5%.

“We are extremely pleased to have Nuton’s strong continued participation in McEwen Copper,” Rob McEwen stated in a news release. “Together we are exploring new technologies that save energy, water, time and capital in the pursuit of delivering green copper to Argentina and the world, a product that will contribute to the electrification of transportation and the protection of our atmosphere.”

Also in February 2023, FCA Argentina S.A., a subsidiary of Stellantis N.V., one of the world’s leading automakers, invested ARS $30 billion in McEwen Copper. In October 2023, Stellantis invested an additional ARS $42 billion, bringing its current stake in McEwen Copper to 19.4%.

“We are delighted to have Stellantis as a partner in the future development of our Los Azules copper project,” Rob McEwen said of the investment. “Together, we share a vision to build a mine for the future based on regenerative principles that can achieve net-zero carbon emissions by 2038.”

Following the capital raise, McEwen Copper is well-funded to advance its Los Azules Project, with a Feasibility Study planned for Q1 2025. MUX strategically reduced its interest to increase its treasury, in order to reduce debt and fund the further development of its gold and silver assets.

Gold & Silver Projects

The Fox Complex

McEwen Mining owns a 100% stake in the Fox Complex in the heart of a prolific gold district in Timmins, Canada.

“When MUX bought the Fox Complex, in late 2017, it was a distressed asset with a history of high operating cost/oz. While it has taken longer than I expected, the cost to produce an ounce of gold is significantly lower,” CEO Rob McEwen stated in a news release.

McEwen Mining issued 2024 guidance for its cash cost/oz at the Fox Complex of $1,225-1,325 on annual production of 40,000-42,000 GEOs. Fox Complex produced 44,450 GEOs in 2023, which was within the company’s guidance range.

Located in one of the most prolific gold production areas in the world, along the Destor-Porcupine Fault Zone within the Abitibi Greenstone Belt, the Fox Complex includes the Black Fox mine and Froome mine which together have yielded over 1,000,000 ounces of gold to date. Also, the complex includes the Grey Fox and Stock deposits that have over 1,800,000 ounces in gold resources. The 2.7-billion-year-old Abitibi Greenstone Belt, formed by ancient volcanic activity, has proved to be one of the world’s richest and most abundant gold regions, with a total gold content currently estimated at over 300 million ounces.

In 2024, MUX commenced development of underground ramp access to the Stock orebodies at the Fox Complex. This development will become the primary source of feed following the completion of mining the Froome deposit in 2026. As part of the future mining sequence initiative, the company has already reported a 31% year-over-year increase of gold resources at Stock West and Stock Main (historical Stock Mine), with confirmation of good grading structures plunging to depth. It has also identified Stock East as a potential new near-term source of future revenue.

The Gold Bar Mine

McEwen Mining owns a 100% stake in the Gold Bar mine, located in an area well known for gold production, the southern Roberts Mountains of the Battle Mountain-Eureka-Cortez gold trend in Eureka County, Central Nevada. The Gold Bar mine is on the same geological structure, 25 miles south of Nevada Gold Mines, a Barrick-Newmont joint venture, part of the Cortez-Goldrush complex. This complex contains estimated reserves and resources of over 50 million gold ounces, with an annual production of 1,000,000 gold ounces.

Gold Bar had been mined between 1991 and 1994, producing 134,000 gold ounces. A new facility was built by MUX in 2019. Gold Bar accounted for 42,700 GEOs in 2023, within the company’s guidance for the year. For 2024, McEwen Mining issued guidance of 40,000-43,000 at a cash cost of $1,450-1,550. The first half of the year is expected to deliver higher production relative to the second half, due to a scheduled waste stripping phase in the Pick pit, in preparation for the 2025 mining program.

Notably, in April 2024, McEwen Mining announced its entry into a definitive agreement and plan of merger with Timberline Resources Corporation (TSX.V: TBR) (OTCQB: TLRS) in a transaction valued at roughly $18.8 million. The merger with Timberline is expected to augment McEwen’s existing portfolio of development and exploration projects in Nevada, leveraging synergies between Timberline’s projects and the Company’s Gold Bar mine.

El Gallo/Fenix

Project Fenix is the proposed redevelopment plan for McEwen Mining’s El Gallo Complex in Mexico. There is a long history of mining in this region. MUX began operating it as an open pit, heap leach mine in 2013, which produced 281,000 gold equivalent ounces at average cash cost of $655 per ounce. Due to the transition to deeper sulfide mineralization that is not amenable to heap leaching, mining activities ceased in the second quarter of 2018 and residual heap leaching followed until mid-2022. The redevelopment plan envisions constructing a mill at the existing mine site that will initially reprocess the existing heap leach material, then transition to open pit mining and processing of the sulphide mineralization. The company recently acquired a complete process plant on very advantageous terms that has considerably reduced the projected capital requirements for the project.

CEO Rob McEwen stated in a news release, “This acquisition has made Fenix more attractive to build and could provide a new long life mine for McEwen Mining.”

The initial development approach is to build a mill to reprocess the material on the heap leach pad and produce approximately 17,000 oz of gold annually for eight years. Construction of the Fenix project is expected to begin in the second half of 2024.

San José Mine

McEwen Mining is a 49% owner and non-operator of the San José gold and silver mine, located in Santa Cruz province, Argentina, encircling Newmont’s prolific Cerro Negro (approx. 300,000 gold ounces produced in 2023). This high-grade underground mine has been operating since 2007 and currently has an expected life of six years with a reserve grade of 296 gpt silver and 5.4 gpt gold.

Exploration is continuing to extend high-grade veins and discover new veins at the complex. San José’s drilling programs to define additional resources and reserves have a long history of success due to a high vein density, aided by good geophysical response from hidden veins.

Production guidance for 2024 for MUX’s 49% interest is 50,000-60,000 GEOs. As a minority shareholder in the mine, MUX equity accounts for its investment in San José, and receives 49% of the dividends from the mine’s free cash flow.

Market Outlook

Mining stocks suffered significant losses in the wake of the COVID-19 pandemic. However, this has turned, and many analysts now forecast a gold bull market in 2024 and beyond.

“The operating challenges we faced in recent years have severely damaged our credibility with our shareholders and the market. As a result, few investors have taken a close look recently at our assets,” Rob McEwen said in a news release. “If they did, I believe some would see the potential value that I see today… I believe there is considerable potential value in MUX, and that is a big reason why I have a personal financial commitment of $220 million in MUX and McEwen Copper.”

Management Team

Robert R. McEwen is Chairman, CEO and Chief Owner of McEwen Mining. He has been associated with the gold industry all his career, with his first 18 years in the investment industry and, since 1990, as CEO of several gold mining companies. He founded Goldcorp and took that company from a $50 million market capitalization to more than $8 billion. He owns 17% of McEwen Mining and is in complete alignment with investors – his investment in MUX and McEwen Copper is $220 million and he takes an annual salary of only $1. He was awarded the Order of Canada and the Queen Elizabeth’s Diamond Jubilee Award, was inducted into the Mining Hall of Fame, was named an Ernst and Young Entrepreneur of the Year and has Honorary Doctor of Law degrees from York University and Western University.

William Shaver is interim COO and a Director of McEwen Mining. He has decades of management and executive experience in mine design, construction and operations. He was a founder of Dynatec Corporation, which became one of the leading contracting and mine operating groups in North America. In 2013, he was recognized as Ernst and Young Entrepreneur of the Year. Most recently, he served as COO of INV Metals. He is a Professional Engineer with a B.Sc. in Mining Engineering from Queens University.

Perry Ing is interim CFO at McEwen Mining. He has 25 years of experience in the Canadian mining industry. Over the past 15 years, he has held positions as CFO of Mountain Province Diamonds, Kirkland Lake Gold and McEwen Mining. Prior to that, he worked at Barrick Gold and Goldcorp and started his career in the mining practice at PwC. He has a Bachelor of Commerce from the University of Toronto and is a Chartered Professional Accountant in Canada and Certified Professional Accountant in the U.S.

Adrian Blanco S. is the company’s Director of Operations for America and Mexico. He has extensive international experience in several industrial sectors and has held executive positions in Mexico, the United States, Peru and Argentina. He joined the McEwen Mining team in 2015 and has led a successful business transformation toward operational discipline, best business practices and financial profitability at subsidiaries Compañia Minera Pangea and McEwen Mining Nevada. He graduated from an Executive Management Program at IPADE and Harvard Business School.

Michael Meding is Vice President and General Manager of McEwen Copper. He has over 20 years of international experience, primarily with major mining companies such as Barrick Gold and Trafigura, including extensive experience with project development and operations in Argentina. While at Barrick Gold’s Veladero mine in Argentina, Mr. Meding played a key role in the turnaround, extension of the mine life and subsequent strategic partnering with Shandong Gold. He holds an MBA from Indiana University in Pennsylvania and an MBA from the Leipzig Graduate School of Management in Germany.

McEwen Mining Inc. (NYSE: MUX), closed Monday's trading session at $10.75, up 1.1289%, on 692,870 volume. The average volume for the last 3 months is 929,968 and the stock's 52-week low/high is $5.92/$12.50.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.